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Abstract
α-Piperidine-β-sulphone hydroxamates were explored that are potent for MMP-2, -9 and -13 that are
sparing of MMP-1 with good pk in the rat. An unexpected decarbonylation led to the hitherto unknown
and α-sulphone hydroxamates that are superior to the corresponding β -sulphones in potency for target
MMP’s, selectivity versus MMP-1, and oral exposure when dosed orally. α-Piperidine-α-sulphone
hydroxamate SC-276 was advanced through antitumor and anti-angiogenesis assays and selected for
development.
Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent enzymes responsible for the remodeling and
degradation of all components of the extracellular matrix.1 The upregulation of MMPs has been implicated
in numerous disease states.2-6 including osteoarthritis7 and cancer8-11 MMPs are essential for tumor growth
and metastasis,12 and inhibition of MMP-9 can block metastasis.13,14 It is recognized that most of the
proteolytic activity associated with tumors in located in the stroma, representing either a defense reaction
by surrounding tissues, or a recruitment process.
Until recently, clinical trials with MMPi’s for advanced cancer had not been successful in demonstrating
efficacy.15,16 Bramhall has reported the first placebo-controlled double-blind study reporting success in
treating cancer with an MMPi in a study treating gastric cancer patients with the broad-spectrum inhibitor
marimastat.17 A survival benefit has also been recently demonstrated in glioblastoma multiforme patients
on marimastat in combination with temozolomide, providing additional support that MMPi’s can improve
the outcome of cancer patients.18 Marimastat afforded a survival rate similar to gemcitabine in patients
with unresectable pancreatic cancer.19 Thus, the proof-of-principle for efficacy in treating human cancers
with MMPi’s has now been demonstrated. Clinical studies are also presently underway with BMS-275291
for the treatment of cancer.20
Inhibition of MMP-1 has been hypothesized21 to be the cause of the musculoskeletal syndrome (MSS)
observed clinically with broad-spectrum inhibitors including marimastat. We therefore have concentrated
our efforts on potently inhibiting selected MMPs while sparing MMP-1. The strategy of avoiding inhibition
of MMP-1 has been applied to succinate MMP inhibitors by British Biotech.22 Cross inhibition of ADAMs
and ADAMTSs may also partially account for side effects observed in long-term MMPi therapy.20

We have previously described the synthesis and MMP inhibitory activity of a series of α-amino-β-sulphone
hydroxamates [Becker BMCL 2001 2719] and α-alkyl- α-amino-β-sulphone hydroxamates23,24 as potent
inhibitors of MMP-2 and MMP-13 that spare MMP-1. These compounds had moderate pharmacokinetic
parameters and required enantioselective syntheses to access the individual enantiomers. We wanted to
remove the chirality and improve the pharmacokinetic profile by incorporating an spiro ring alpha to the
hydroxamate to reduce potential metabolic degradation of the hydroxamate moiety. It should be noted in
this context that the α-tetrahydropyran β-sulphone RS-130,83025 synthesized by Roche Bio-Science has
been advanced to Phase II clinical trials for osteoarthritis.26 During our examination of the β-sulphones
series we discovered α-sulphone hydroxamate inhibitors, which are superior to the β-sulphone series in
both enzyme profile and ADME properties.27-28 A series of α-sulphone hydroxamates has also been
reported by the Wyeth group.29,30
This manuscript will highlight our initial efforts in the β-sulphone and α-sulphone aryl ether hydroxamate
series resulting in the discovery of SC-276, an MMP-1 sparing inhibitor which shows excellent efficacy in
tumor xenograft models.
Chemistry
The β-sulphone derivatives were prepared from N-BOC ethyl isonipecotate 131 as illustrated in Scheme 1.
Deprotonation of 1 with LDA and quenching with methylene diiodide gave iodomethyl derivative 2.
Alkylation of the sodium salt of 4-mercapto-diphenyl ether with 2 gave the corresponding sulfide which
was oxidized directly with MCPBA to afford the sulphone 3. Removal of the BOC group with HCl gave
amine 4, and alkylation of the piperidine with an alkylating agent or via reductive amination gave the Nalkyl amine 5. Saponification of the ethyl ester with sodium hydroxide gave the carboxylic acid 6 which
was coupled with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine utilizing EDC as the coupling reagent.
Deprotection under acidic conditions gave the β-sulphone hydroxamate 7.
We desired the dimethyl ketal 8 as an intermediate for facile elaboration of the α-position via the ketone
moiety to afford various a-substituted-β-sulphone hydroxamates. Toward this end we alkylated 4-mercapto
diphenyl ether 10 with bromopyruvic acid in methanol (Scheme 2) to afford the α -keto acid 11. Oxidation
of the sulfide to the sulphone followed by conditions of esterification with thionyl chloride in methanol
proceeded with an unexpected decarbonylation to afford the α-sulphone 12. Direct treatment of the methyl
ester 12 with hydroxylamine gave the corresponding hydroxamic acid 13.
The α,α-dimethyl-α-sulphone 17 was prepared as shown in Scheme 3. Alkylation of 4-phenoxythiophenol
with t-butyl bromoacetate and oxidation of the resulting sulfide gave the sulphone 14. Dialkylation with
methyl iodide and sodium hydride gave the dimethyl sulphone 15. Removal of the t-butyl ester with TFA
gave the carboxylic acid which was coupled with hydroxylamine in the presence of EDC to give the α,αdimethyl hydroxamic acid 17.
The alpha-THP sulphone 21 was prepared as shown in Scheme 4. Alkylation of 4-fluorothiophenol with
methyl bromoacetate gave the sulfide which was oxidized with oxone to afford sulphone 18. The acidic
methylene was dialkylated with bis(2-bromoethyl)ether to afford the α-sulphone 19. Saponification of the
methyl ester with potassium trimethylsilanoate and subsequent coupling of the carboxylic acid with O(tetrahydro-2H-pyran-2-yl)hydroxylamine (THP-hydroxylamine) utilizing the water-soluble carbodiimide
reagent (EDC) gave the THP protected hydroxamate 20. Displacement of the fluoride with 4chlorophenolate anion and subsequent treatment with HCl gave the free hydroxamate 21.
N-alkylpiperidine phenyloxyphenyl α-sulphones were synthesized as described in Scheme 5. Ethyl N-BOC
isonipecotate 1 was deprotonated with LDA and sulfinylated with the disulfide of 4-mercaptodiphenyl ether
to give the sulfide 22, and oxidation with MCPBA afforded the corresponding α-sulphone 23. Removal of
the BOC protecting group under acidic conditions gave the free piperidine 24 which was either directly
alkylated or reductively alkylated to afford 25. Saponification of the hindered ethyl ester proceeded under
basic conditions and the resulting carboxylic acid 26 was coupled with THP-hydroxylamine employing
ECD. Acidic deprotection of the hydroxamate moiety afforded the requisite hydroxamate 27 as the
hydrochloride salt.

N-Alkylpiperidine phenylthiophenyl α-sulphones 35a-h were prepared as exemplified in Scheme 4. Ethyl
N-BOC isonipecotate 1 was sulfinylated with p-fluorophenyldisulfide after deprotonation with LDA to
afford the sulfide 29, and subsequent oxidation with MCPBA gave the corresponding α-sulphone 30.
Acidic removal of the BOC group gave the free amine 31 as the hydrochloride salt which was then
alkylated with an alkyl halide or via reductive amination to yield 32. The p-fluoro was then displaced via a
nucleophilic aromatic substitution reaction with thiophenol to yield thioether 33. Basic saponification of
the hindered ethyl ester gave the carboxylic acid, which was coupled with THP-hydroxylamine utilizing
EDC to give the protected hydroxamate 34. Removal of the THP group with HCl gave the desired αsulphone hydroxamate 35 as the hydrochloride salt for basic amines. Alternatively, as shown in Scheme 7,
the fluoro of N-BOC sulphone 30 was displaced with thiophenol to afford thioether 36. Removal of the
BOC with HCl gave the amine hydrochloride 37 which was alkylated to give tertiary amine 33.
Biology
Selected α-sulphone and β-sulphone hydroxamates were tested for inhibitory potency versus MMP-1, 2, 3,
8, 9, and 13. Table 1 summarizes the MMP inhibitory potency of β-sulphone analogs, and includes RS130,830 as a direct comparator. We utilized the diphenyl ether moiety that we had utilized in our earlier βsulphone work, as it had enabled the production of analogs that were potent for MMP-2 and MMP-13,
typically with >1000-fold selectivity versus MMP-1.23,24 Compounds 7a through 7e are phenylthiophenyl
ethers with varying substituents on the α-piperidine nitrogen, and compound 7f employs a 3,4dimethylphenylthiophenyl sulphone to drive deeper into the P1’ selectivity pocket and enhance the
selectivity. The MMP-2 selectivity ratio of 7a through 7d persists at between 860X (example 7b) to 2400X
(example 7a) relative to a selectivity ratio of 2000X for RS-130830. Somewhat higher selectivity (8500X)
was attained with N-propargyl piperidine 7e, although the potency for MMP-2 was attenuated 3-4X relative
to the other analogs. The free NH compound 7b was roughly an order of magnitude less potent versus all
enzymes tested, which was surprising. It is possible that the compound was unstable under the conditions
of the assay leading to diminished potency. We were hoping for an enhancement in exposure in the rat for
the α-piperidine derivatives versus the α-THP RS-130830. Propargyl compound 7e did exhibit a higher
Cmax of 8038 µg/mL, but the concentration at 6 hours was lower for all of these analogs relative to the
neutral compound RS-130830.
As mentioned, we originally targeted ketal 8 to further our exploration of β-sulphone hydroxamates via
elaboration of the ketone derived from the ketal, but Oxone® oxidation of a-keto acid 11 followed by
standard conditions to form the methyl ester afforded the decarbonylated methyl ester 12. When αsulphone hydroxamate 13 was subsequently prepared and tested, we were not expecting particularly potent
inhibition of the target MMPs because the hydroxamate is known to serve as a tight chelator for the zinc in
the active site, and one of the sulphone oxygens forms an energetically favorable H-bond with the NH of
Ala-161 in the enzyme. This is analogous to the binding of amino acid sulphonamide hydroxamates and
corresponds to those well-known MMP inhibitors in terms of digitization. Thus, we were surprised and
delighted to find that the unsubstituted α-sulphone 13 maintained good inhibitory potency of 5 nM versus
MMP-13, 2.6 nM versus MMP-2, and was selective versus MMP-1 (IC50 = 6600 nM). Indeed, we were
then the first to report α-sulphone hydroxamates as potent MMP inhibitors.27,28 Aranapakam and
coworkers at Wyeth have recently reported novel series of α-sulphones that are potent for MMP-13 and
sparing of MMP-1, including a compound that is efficacious in an advanced rabbit osteoarthritis model.29,30
With the potency of α-sulphone 12 established, we prepared the α,α-dimethyl analog 17 which boosted the
potency back to sub-nanomolar values, and actually exceeded the potency of the β-sulphones with an IC50
values for MMP-13 and MMP-2 of 0.25 nM and 0.1 nM, respectively. The α-sulphone 17 is also more
potent for MMP-1 (IC50 = 220 nM) but is still >2000X sparing of MMP-1 relative to MMP-13. We thus
determined to make the corresponding α-piperidine diaryl ethers and diaryl thioethers 9 (X = O and X = S,
respectively). We also prepared the α-THP 21 corresponding to the Roche α-THP RS-130830 for a direct
comparison of the b- and α-sulphones (Table 2). We have found, in general, that α-sulphones are more
potent versus target MMP isozymes and also have superior pharmacokinetics relative to the β-sulphones.
Specifically, relative to RS-130830, compound 21 is approximately 4X more potent versus MMP-2, 3X
more potent against MMP-9, and 4X more potent versus MMP-13. Compound 21 is twice as potent versus
MMP-1, so the selectivity ratio is actually improved. Potency for MMP-3 remains essentially unchanged.

When administered orally to the rat, compound 21 has twice the Cmax, although the concentration at 6 hours
is comparable. The t1/2 is identical at 1.5 h (data was only collected to 6 hours, hence the t1/2 is less that
would be measured for a full 24 h data collection). Strikingly, the BA for α-sulphone 21 (45.8%) is double
the value for RS-130830 (22%) in this direct head-to-head comparison. This higher bioavailability and
Cmax may be due to greater steric bulk around the hydroxamate, protecting it from the usual modes of
hydroxamate metabolism including N-O bond cleavage, hydrolysis, and glucuronidation. It is interesting to
note that the α-sulphone is of slightly lower molecular weight relative to the β-sulphone and has one less
rotatable bond. Veber has predicted improved BA for compounds with fewer rotatable bonds.32
Table 3 summarizes the MMP inhibitory potency for diphenyl ether α-sulphone analogs and includes rat pk
data for selected analogs. It should be noted for the rat pk in Tables 1 through 4 that plasma concentrations
were measured only out to 6 hours. This protocol enables a higher throughput of compounds for rat pk, but
leads to an underestimation in particular of the half life (t1/2) of the compounds. It nonetheless allows a
direct comparison among analogs for advancement selection criterion. In general, these analogs are very
potent versus the target enzymes MMP-2, MMP-9 and MMP-13, and quite sparing of MMP-1. N-methyl
analog 27c, for example, is 4600X selective for MMP-2 and MMP-13 over MMP-1. Comparable potency
and selectivity would be expected for most of these analogs, given that the P1’ substituents is held constant,
which occupies the S1’ selectivity pocket. As in the β-sulphone series, the secondary amine 27b was
notably less potent than the other analogs in the series, and mesyl compound 27i was somewhat less potent
as well. Secondary amine 27b did have the longest t1/2 of 1.8 h among these compounds, but suffers from a
lower BA of 16% as compared with the tertiary amine compounds tested. N-Methyl piperidine 27c showed
good exposure and the highest bioavailability (59%) of the series, while N-cyclopropyl piperidine 27e had
a Cmax of 15,720 ng/mL and a good BA of 36%. N-propargyl piperidine 27g exhibited the highest oral
exposure of these analogs, with a very high Cmax of 22,882 ng/mL and a significant concentration (345
ng/mL) remaining after 6 h. The N-propargyl analog also had a good BA of 35.5%.
The improvement of the α-sulphones over the β-sulphones is again clearly borne out in the direct
comparison of N-propargyl piperidine phenyloxyphenyl β-sulphone 7e and the corresponding α-sulphone
27g (Figure 3). The α-sulphone 27g is almost twice as potent at MMP-1, but it is 3X as potent at MMP-2,
9X as potent at MMP-9 and over 2X as potent at MMP-13. The exposure in rat after an oral suspension
dose of 20 mpk was substantially greater for 31, with a Cmax of 22,882 µg/mL and a concentration at 6 h of
345 µg/mL, compared with a Cmax of 8038 µg/mL and C6h of 49 µg/mL for 7e.
We then prepared the phenylthiophenyl ether α-sulphones as summarized in Table 4 in order to enhance the
selectivity versus MMP-1. These compounds were still highly potent, although slightly less potent relative
to the phenyloxyphenyl ethers of Table 3. These thioethers have the advantage of exquisitely MMP-1
sparing, with all examples shown having selectivity ratios of >10,000X for MMP-2 over MMP-1, with the
exception of N-mesyl piperidine 35g. N-cyclopropyl piperidine 35d, for example, is very potent for MMP2 (IC50 = 0.1 nM) with an IC50 for MMP-1 of >10,000 nM. Cyclopropyl compound 35d is also very potent
for MMP-13 (0.2 nM) and has moderate potency for MMP-9 (2.5 nM). The tertiary amines tested exhibit
very good pk in the rat after oral suspension dosing. N-Cyclopropyl derivative 35d has a significant Cmax
of 7647 ng/mL and a substantial amount remaining after 6 h (529 ng/mL), with a good BA of 34.6%. Nmethoxyethyl piperidine also enjoyed good exposure, as did N-propargyl piperidine SC-276, with a Cmax of
13,630 ng/mL, and 281 ng/mL remaining after 6 h. SC-276 was selected for further study based on its
excellent in vitro and in vivo pharmacokinetic parameters.
Anti-angiogenic and anti-tumor properties of SC-276
The growth of solid tumors has been shown to be dependent on the development of new blood vessels.33
Avascular, microscopic growing tumors produce diffusible angiogenic factors that induce host capillary
endothelial cells to proliferate, migrate and form new vessels in a process called tumor-induced
angiogenesis. Once vascularized, tumor size can increase almost exponentially.34-36 To address the

question of whether SC-276 is anti-angiogenic in vivo and therefore might inhibit tumor growth by
inhibiting angiogenesis, we tested SC-276 in a mouse model of corneal neovascularization.

The mouse corneal micropocket assay is a widely used model of angiogenesis useful for in vivo testing of
anti-angiogenic agents. Hydron pellets containing basic fibroblast growth factor (bFGF) were implanted
into the corneas of mice. Pronounced neovascularization occurred in the tissue surrounding the pellet of the
course of 4 days. Mice were administered vehicle or SC-276, orally, twice a day beginning the evening of
pellet implantation. On day 5, animals were sacrificed and corneal neovascularization was determined by
computer-aided image analysis. SC-276 inhibited bFGF-induced corneal neovascularization in a dosedependent manner (Fig 6). SC-276 reduced corneal neovascularization approximately 50% at a dose of 50
mpk and supports the hypothesis that the anti-tumor activity of SC-276 is due, at least in part, to inhibition
of tumor angiogenesis.

Inhibition of Tumor Growth by SC-276

Matrix metalloproteinase inhibitors (MMPi) may be most useful in the human clinical setting when used in
combination with chemotherapy. We tested SC-276 as single agent and in combination with Taxol, a
chemotherapeutic used in the treatment of breast cancer. The Kaplan-Meier survival curves for the various
treatment groups are presented in Fig 7. MX-1 carcinomas grew progressively and rapidly in mice that
received vehicle only; the median survival time (MDS) was 25.3 days. A MDS value of 32.2 days was
calculated for the mice treated with 100 mg/kg of SC-276. All tumors in this group reached the cut cut-off
size of 1.5 g. The 32% increase in the MDS of the SC-276-treated mice was statistically significant when
compared to the MDS of vehicle-treated mice (p < 0.00001). Eight of the 9 mice treated with Taxol had a
MDS of 30.1 days. The 19% increase in survival compared to vehicle-treated mice was statistically
significant (p=0.036). One mouse died from unknown causes on Day 13 and was not included in the
analysis.

Excellent activity was seen when Taxol and SC-276 were combined. The MDS of the mice treated with
Taxol and SC-276 was 46.7 days and represents a survival increase of 53% over the MDS of the mice
treated with Taxol alone. These results clearly show that the combination of Taxol and SC-276 exceeds the
efficacy of Taxol alone as demonstrated by the increased median survival time of mice bearing MX-1
tumors. Moreover, the survival benefit appears to be more than additive when compared to the efficacy of
monotherapy with either agent (Table 5).

Crystallography and Modeling of α-Sulphones and β-sulphones
Joe McDonald Discussion of structure & modeling, selectivity vs. MMP-1 and Arg214 [Refs: a & b, Moy,
2000, etc……]
Conclusions
The β-sulphone series provided potency for the targeted MMPs and selectivity versus MMP-1, but
generally exhibited poor oral exposure (Table 1). In addition, we have observed that some β-sulphones
with α-hydrogens can undergo β-elimination. In contrast, the α-sulphones possess both potency and
selectivity and provide an improvement in oral exposure demonstrated by higher Cmax value and
bioavailability. Both the aryl ether and thioether P1’ moieties provide excellent potency(Tables 3 and 4,
respectively), but the thioether moiety exhibits enhanced selectivity over the phenyloxyphenyl sulphones.
The α-piperidine nitrogen substituents provide improved ADME properties, and compounds exhibiting the
highest oral exposures are those with the methoxyethyl, cyclopropyl, allyl and propargyl groups (35c, 35d,
35e and SC-276). This work culminated in the discovery of SC-276, a thioether sulphone hydroxamate that
shows excellent efficacy in murine xenograft tumor models and anti-angiogenesis assays.
SC-276 exhibits excellent potency for target enzymes, selectivity versus MMP-1, good pk in multiple
species, and excellent efficacy in tumor xenograft models. Primate pk for SC-276 was excellent, with BA
= 88% in cyno and a t1/2 of 3.8 h. The compound has been slated for development and has been prepared
on a multi-kilo scale. Additional results will be reported in due course.
Experimental Section
General Procedures and Analysis. All solvents and reagents were used without further purification
unless otherwise noted. All reactions were performed under an atmosphere of nitrogen or argon. Merck
silica gel 60 (230-400 mesh) was used for flash chromatography. Merck Kieselgel 60 F254 DCFertigplatten (0.25 mm, Art. 5719) were used for TLC. High performance liquid chromatograms (HPLC)
were obtained from YMC AQ C-18 reverse phase columns. 1H NMR spectra were obtained from either
General Electric QE-300 or Bruker-400 MHz Ultrashield spectrometers with tetramethylsilane (TMS) as an
internal standard. Noise-decoupled and APT 13C NMR spectra were recorded at 75 MHz on a General
Electric QE-300 spectrometer. IR spectra were recorded on a Perkin Elmer 685 spectrophotometer. DSC
refers to differential scanning calorimetry. MIR refers to multiple internal reflectance infrared
spectroscopy. High-resolution mass spectra were recorded on a Finnigan MAT8430 instrument. Elemental
analyses were conducted on a Control Equipment CEC240-XA instrument. Melting points are obtained by
differential scanning calorimetry.
1-tert-Butyl 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate (2). To a solution of ethyl
isonipecotate N-t-butyl carbamate 1 (1.00 g, 3.89 mmol) in dry THF (10 mL) at -40°C was added 1.8 M
LDA (2.2 mL, 3.9 mmol) dropwise. After 0.5 h at -40°C the reaction was quenched with water and
extracted with diethyl ether (3X). The combined extracts were washed with water and brine and dried over
MgSO4. Concentration gave the desired iodide 2 (1.5 g, 96.8%) as an oil: 1H NMR (400 MHz, CDCl3) δ

4.23 (2H, t, J = 7 Hz), 3.83 (2H, m), 3.30 (2H, s), 3.00 (2H, m), 2.18 (2H, m), 1.42 (9H, s), 1.28 (3H, t, J =
7 Hz).
1-tert-Butyl 4-ethyl 4-{[(4-phenoxyphenyl)sulfonyl]methyl}piperidine-1,4-dicarboxylate (3). To a
suspension of sodium hydride (600 mg of a 60% dispersion, 15.0 mmol) in dry DMF (9 mL) at 0°C was
added 4-phenoxy thiophenol (3.03 g, 15.0 mmol) in dry DMF (1 mL) and stirred for 15 min at 0°C. The
sodium thiolate solution was then added to a solution of iodide 2 (5.96 g, 15.0 mmol) in DMF (9 mL) at
0°C and the solution was stirred for 1 h at 0°C and 3 h at rt. The reaction was quenched with the addition
of water (100 mL) and the resulting mixture was extracted with EA (3X). The combined extracts were
washed successively with water, 1N KHSO4, water and brine and dried over MgSO4. Concentration gave a
residue (7.42 g) which was purified by chromatography on silica gel eluting with EA/hexane (20/80) to
afford the desired sulfide (6.27 g, 89%) as a solid: HRMS calcd for C26H33NSO5 471.2063, found
471.2052. To a solution of the sulfide (6.2 g, 13.1 mmol) in CH2Cl2 at 0°C was added 85% MCPBA (5.65
g, 27.8 mmol) and then the reaction was stirred for 2 h at 0°C. The solution was then washed successively
with water, saturated NaHCO3, water, and brine, and then dried over MgSO4. Concentration gave a
residue (7.86 g) which was chromatographed on silica gel eluting with EA/hexane (30/70) to afford the βsulphone 3 (6.4 g, 97%) as a colorless solid.
Ethyl 4-{[(4-phenoxyphenyl)sulfonyl]methyl}piperidine-4-carboxylate hydrochloride (4). Through a
solution of sulphone BOC amine 3 (1.11 g, 4.03 mmol) in EA (30 mL) at 0°C was bubbled HCl gas for 5
min. Concentration gave a colorless solid which was triturated with ether, filtered and dried to afford the
amine hydrochloride 4 (774 mg, 80%) as a colorless solid: 1H NMR (300 MHz, CD3OD) 7.88 (2H, d, J = 9
Hz), 7.46 (2H, t, J = 8 Hz), 7.27 (1H, t, J = 8 Hz), 7.12 (4H, t, J = 8.5 Hz), 4.19 (2H, q, J = 7 Hz), 3.69 (2H,
s), 3.32 (2H, m), 3.16 (2H, td, J = 10, 3 Hz), 2.39 (2H, m), 2.00 (2H, m), 1.31 (3H, t, J = 7 Hz). IR (MIR)
1722, 1583, 1486, 1246, 1146 cm-1. Anal calcd for C21H25NSO5.HCl C, 57.33; H, 5.96; N, 3.18; Cl, 8.06.
Found 57.29; H, 5.87; N, 3.17; Cl, 8.17.
tert-Butyl 4-[(hydroxyamino)carbonyl]-4-{[(4-phenoxyphenyl)sulfonyl]methyl}piperidine-1carboxylate (7a). To a solution of ethyl ester 3 (250 mg, 0.496 mmol) in 1:1 EtOH/THF (6 mL) was
added NaOH (198 mg, 4.96 mmol) in water (2 mL) and the solution was heated at 60°C for 18 h. The
reaction was diluted with water (20 mL) and acidified with 2N HCl. The mixture was then extracted with
CH2Cl2 (3X). The combined extracts were washed with brine and dried over MgSO4 and concentrated to
afford the carboxylic acid 6a (236 mg, 100%). 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 8 Hz), 7.41
(2H, t, J = 8 Hz), 7.22 (1H, t, J = 7 Hz), 7.06 (4H, d, J = 7 Hz), 3.68 (2H, m), 3.48 (2H, s), 3.32 (2H, m),
2.21 (2H, m), 1.71 (2H, m), 1.45 (9H, s).
To a solution of the carboxylic acid 6a (850 mg, 1.79 mmol) in DMF (7 mL) was sequentially added
HOBT (290 mg, 2.1 mmol), EDC (480 mg, 2.5 mmol), NMM (0.59 mL, 5.37 mmol) and 50% aqueous
hydroxylamine (0.35 mL, 5.37 mmol), and the solution was stirred at rt for 16 h. Water (35 mL) was added
and the mixture was extracted with EA (4 X 50 mL). The combined extracts were washed successively
with water and brine and dried over MgSO4. Concentration gave a residue (900 mg) which was
chromatographed on reverse phase eluting with MeCN/H2O (gradient from 30/70 to 80/20) to afford the
desired hydroxamate 7a (300 mg, 34%) as a colorless solid: 1H NMR (400 MHz, CDCl3) δ 7.85 (2H, d, J =
8 Hz), 7.48 (2H, t, J = 8 Hz), 7.28 (1H, t, J = 7 Hz), 7.15 (4H, d, J = 7 Hz), 3.66 (2H, s), 3.42 (2H, m), 3.18
(2H, m), 1.91 (2H, m), 1.65 (2H, m), 1.38 (9H, s); Anal calcd for C24H30N2SO7 C, 58.76; H, 6.16; N, 5.71;
S, 6.54. Found C, 58.64; H, 6.24; N, 5.66; S, 6.66.
N-hydroxy-4-{[(4-phenoxyphenyl)sulfonyl]methyl}piperidine-4-carboxamide hydrochloride (7b).
Through a solution of N-BOC hydroxamate 7a (499 mg, 1.02 mmol) in EA (20 mL) at 0°C was bubbled
HCl gas for 2 min. The solution was then stirred for 0.5 h at 0°C and then concentrated to dryness. The
residue was triturated with ether and dried to afford the hydrochloride salt of hydroxamate 7b (432 mg,
99%) as a colorless solid: 1H NMR (400 MHz, d6-DMSO) δ 8.78 (1H, s), 8.65 (1H, br s), 3.18 (2H, m),
2.91 (2H, m), 2.16 (2H, m), 1.95 (2H, m). HRMS calcd for C19H22N2SO5 391.1328, found 391.1349. Anal

calcd for C19H22N2SO5.HCl.H2O C, 51.29; H, 5.66; N, 6.30; Cl, 7.97; S, 7.21. Found C, 50.87; H, 5.24;
N, 6.22; Cl, 8.24; S, 7.07.
N-hydroxy-1-(3-methoxybenzyl)-4-{[(4-phenoxyphenyl)sulfonyl]methyl}piperidine-4-carboxamide
hydrochloride (7c). To a solution of the ethyl ester piperidine monohydrochloride 4 (748 mg, 1.70 mmol)
in methanol (7 mL) was added anisaldehyde (242 mg, 1.78 mmol) followed by borane-pyridine complex
(106 uL of a ca. 8 M solution in pyridine, 0.85 mmol). After 18 h at rt, additional quantities of
anisaldehyde ( 112 mg, 0.82 mmol) and borane-pyridine (106 uL, 0.85 mmol) were added and the solution
stirred for an additional 18 h at rt. Saturated aqueous sodium bicarbonate (10 mL) was then added and the
reaction was extracted with ethyl acetate (3X). The combined extracts were washed with water and brine,
dried over Na2SO4, and concentrated to afford a colorless oil (1.03 g). Chromatography on silica gel
eluting with EA/hexane (1:1) afforded the N-methoxybenzylamine 5c (0.82 g, 92%) as a colorless oil: IR
(MIR) 1731, 1581, 1486, 1242, 1140 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.81 (2H, d, J = 8.7 Hz), 7.42
(2H, t, J = 8 Hz), 7.22 (2H, q, J = 8 Hz), 7.05 (5H, m), 6.85 (2H, m), 6.75 (1H, d, J = 8 Hz). MS MH+
calcd for C29H33NO6S 524, found 524. Anal calcd for C29H33NO6S.0.75H2O C, 64.84; H, 6.47; N, 2.61.
Found C, 64.89; H, 6.72, N, 2.51.
To a solution of 3-methoxybenzylamine 5c (800 mg, 1.53 mmol) in EtOH (10 mL) and THF (15 mL) was
added an aqueous solution of NaOH (612 mg, 15.3 mmol) in water (15 mL) and the solution was heated
under reflux for 16 h. The reaction mixture was concentrated, and 5.5N aqueous HCl (15 mL) was added
followed by MeOH (20 mL) to affect dissolution of the resulting gum. Purification on a Waters reversephase instrument eluting with 15/85 MeCN/H2O with 0.5% HCl afforded the corresponding carboxylic acid
6c as a yellow-orange oil. IR (MIR) 3500 (br), 3200-2300 (br), 1581, 1486, 1244, 1142 cm-1; HRMS
calcd for C27H29NO6S 496.1798, found 496.1794. 1H NMR (300 MHz, CD3OD) δ 7.87 (2H, d, J = 8.7 Hz),
7.45 (2H, t, J = 8 Hz), 7.39 (1H, t, J = 8 Hz), 7.26 (2H, m), 6.92 (1H, m), 4.29 (2H, s), 3.83 (3H, s), 3.78
(2H, s), 3.38 (2H, br m), 3.23 (2H, br m), 2.45 (2H, br m), 2.12 (2H, br m).
To a solution of this carboxylic acid 6c (841 mg, 1.62 mmol) in dry DMF (6 mL) was added HOBT (263
mg, 1.94 mmol) and NMM (655 mg, 6.5 mmol). The solution was then cooled to 0°C and 50% aqueous
hydroxylamine (128 uL, 194 mmol) was added followed by EDC (372 mg, 1.94 mmol). After 20 h at rt,
additional quantities of HOBT, NMM, hydroxylamine and EDC (same quantities as original) were added
and the solution was stirred for an additional 16 h at rt. The reaction mixture was then concentrated.
Saturated aqueous NaHCO3 (50 mL) was added and the mixture was extracted with EA (4X). The
combined extracts were washed with water and brine, dried over Na2SO4, and concentrated to afford a
yellow-orange oil (308 mg) which was purified on a Waters reverse-phase instrument eluting with 15/85
MeCN/H2O with 0.5% HCl afforded the requisite hydroxamic acid 7c as a colorless solid: IR (MIR) 1737,
1656, 1583, 1487, 1245, 1144 cm-1; 1H NMR (300 MHz, CD3OD) δ 7.89 (2H, d, J = 8 Hz), 7.5-6.9 (11 H,
m), 4.27 (2H, s), 3.84 (3H, s), 3.55-3.25 (4H, m), 3.06 (2H, m), 2.62 (2H, m), 2.16 (2H, m). HRMS calcd
for MH+ C27H31N2O6S 511.1903, found 511.1907. Anal calcd for C27H30N2O6S.HCl.1.5H2O C, 56.49; H,
5.97; N, 4.88. Found C, 55.92; H, 5.32; N, 4.72.
N-hydroxy-4-{[(4-phenoxyphenyl)sulfonyl]methyl}-1-(2-phenylethyl)piperidine-4-carboxamide
hydrochloride (7d). To a suspension of amine hydrochloride 4 (750 mg, 1.70 mmol) in EtOH (30 mL)
was added phenyl acetaldehyde (414 mg, 3.4 mmol) followed by borane-pyridine (0.44 mL, 3.4 mmol) and
the reaction was stirred at rt for 3 d. The solvent was removed in vacuo and the residue resuspended in
H2O (40 mL). The mixture was extracted with CH2Cl2 (3X) and the combined organic extracts were
washed successively with water and brine, and dried over MgSO4. Concentration gave a residue which was
chromatographed on silica gel eluting with EA/hexane (60/40 to neat EA) to afford the phenethylamine
ethyl ester 5d: 1H NMR (400 MHz, CDCl3) δ 7.81 (2H, d, J = 9 Hz), 7.44 (2H, t, J = 9 Hz), 7.31 (1H, m),
7.24 (5H, m), 7.09 (4H, m), 4.30 (2H, q, J = 7 Hz), 3.50 (2H, m), 3.45 (2H, s), 3.24 (2H, m), 3.12 (2H, m),
2.94 (2H, m), 2.55-2.45 (4H, m), 1.36 (3H, t, J = 7 Hz). HRMS calcd for C29H34NSO5 508.2158, found
508.2161.
To a solution of phenethylamine ethyl ester 5d (680 mg, 1.30 mmol) in 1:1 EtOH/THF (16 mL) was added
an aqueous solution of NaOH (520 mg, 13.0 mmol) in water (3 mL) and the reaction was heated to 60°C

for 16 h. The reaction was then concentrated to dryness and acidified with 2N HCl. Trituration with ether
afforded the carboxylic acid 6d as a beige solid (894 mg): MS MH+ calcd for C27H29NSO5 480, found 480.
To a suspension of the carboxylic acid 6d (850 mg) in DMF (10 mL) was added sequentially HOBT (267
mg, 1.98 mmol), EDC (429 mg, 2.24 mmol), NMM (485 mg, 4.8 mmol) and 50% aqueous hydroxylamine
(1.06 mL, 16 mmol). After 16 h the reaction was charged with identical quantities of HOBT, EDC, NMM
and hydroxylamine and stirred for an additional 24 h. To the reaction was then added H2O (50 mL) and the
mixture was extracted with CHCl3 (3X). The combined extracts were washed successively with water and
brine, dried over MgSO4, and concentrated to afford a residue (380 mg) which was chromatographed on
reverse phase eluting with a gradient of MeCN/H2O /HCl to afford the hydroxamic acid hydrochloride salt
7d (104 mg, 14% from amine 4) as a colorless solid: MS MH+ calcd for C27H30N2SO5 495, found 495. Anal
calcd for C27H30N2SO5.HCl.0.75H2O C, 59.55; H, 6.02; N, 5.14. Found C, 59.29; H, 6.04; H, 5.19. IR
(MIR) 1647, 1580 cm-1.
N-hydroxy-4-{[(4-phenoxyphenyl)sulfonyl]methyl}-1-prop-2-ynylpiperidine-4-carboxamide
hydrochloride (7e). To a solution of amine hydrochloride 4 (750 mg, 1.70 mmol) in DMF (10 mL) was
added K2CO3 (469 mg, 3.4 mmol) followed by 80% propargyl bromide in toluene (0.25 mL, 1.7 mmol).
The reaction was stirred at rt for 5 h and then diluted with EA (40 mL) and washed successively with water
and brine and dried over MgSO4. Concentration gave a residue (730 mg) which was chromatographed on
silica gel eluting with EA to afford the N-propargyl amine ethyl ester 5e (620 mg, 82%) as a solid: IR
(MIR) 3278, 1733, 1581, 1467, 1242, 1142 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.84 (2H, d, J = 9 Hz),
7.42 (2H, t, J = 9 Hz), 7.23 (1H, t, J = 7 Hz), 7.06 (4H, d, J = 9 Hz), 4.21 (2H, q, J = 7 Hz), 3.47 (2H, s),
3.41 (1H, m), 2.83 (2H, m), 2.69 (2H, m), 2.37 (2H, m), 1.96 (2H, m), 1.33 (3H, t, J = 7 Hz).
To a solution of N-propargyl amine ethyl ester 5e (620 mg, 1.4 mmol) in 1:1 EtOH/THF (20 mL) was
added NaOH (560 mg, 14.0 mmol) in water (10 mL) and the reaction was heated to 60°C for 18 h. The
reaction mixture was then concentrated to a residue. Water (40 mL) was added and the mixture acidified
with 2N HCl to pH 4. The resulting precipitate was filtered and dried to afford carboxylic acid 6e (473 mg,
82%) as a solid: 1H NMR (300 MHz, CDCl3) δ 7.85 (2H, d, J = 9 Hz), 7.48 (2H, t, J = 8 Hz), 7.28 (1H, t, J
= 6 Hz), 7.16 (4H, d, J = 9 Hz), 3.53 (2H, s), 3.20 (2H, s), 3.09 (1H, s), 2.48 (2H, m), 2.33 (2H, m), 2.01
(2H, m), 1.06 (2H, m). HRMS calcd for C22H24NSO5 414.1375, found 414.1382. Anal calcd for
C22H23NSO5.HCl.0.5H2O C, 57.57; H, 5.49; N, 3.05; S, 6.99. Found C, 57.59; H, 4.91; N, 2.72; S, 6.76.
To a solution of solution of carboxylic acid 7e (460 mg, 1.10 mmol) in DMF (10 mL) was added
sequentially HOBT (180 mg, 1.33 mmol), EDC (299 mg, 1.56 mmol), NMM (0.49 mL, 4.45 mmol) and
50% aqueous hydroxylamine (0.22 mL, 3.3 mmol) and the reaction was stirred on at rt. The reaction was
then charged again with identical amounts of HOBT, EDC, NMM and aqueous hydroxylamine and stirred
an additional 48 h. Water (30 mL) was added and the reaction was extracted with CHCl3 (3X), and the
combined extracts were washed with brine, dried over MgSO4, and concentrated to afford a residue (500
mg) which was chromatographed on reverse phase eluting with MeCN/H2O (20/80) to afford the Npropargyl hydroxamic acid free base of 7e (173 mg, 36%) as a colorless solid: 1H NMR (400 MHz, d6DMSO) δ 8.63 (1H, s), 7.82 (2H, d, J = 9 Hz), 7.48 (2H, t, J = 9 Hz), 7.27 (1H, t, J = 8 Hz), 7.14 (4H, d, J =
9 Hz), 3.57 (2H, s), 3.19 (2H, s), 3.11 (1H, s), 2.47 (2H, m), 2.32 (2H, m), 201 (2H, m), 1.72 (2H, m).
HRMS calcd for C22H25N2SO5 429.1484, found 429.1480. Anal calcd for C22H24N2SO5 C, 61.66; H,
5.64; N, 6.54; S, 7.48. Found C, 61.33; H, 5.68; N, 6.36; S, 7.35. To a solution of this free base
hydroxamate in MeOH (5 mL) was added a solution of HCl in MeOH [prepared by adding 46 mg (0.66
mmol) of acetyl chloride to MeOH (2 mL) at 0°C]. Concentration and trituration with ether afforded the
hydroxamic acid amine hydrochloride salt 7e (153 mg, 100%) as a colorless solid: Anal calcd for
C22H24N2SO5.HCl.0.5H2O C, 55.75; H, 5.53; N, 5.91; Cl, 7.48. Found C, 55.42; H, 5.63; N, 5.79; Cl, 8.00.
4-({[4-(3,4-dimethylphenoxy)phenyl]sulfonyl}methyl)-N-hydroxy-1-prop-2-ynylpiperidine-4carboxamide hydrochloride (7f). To a suspension of 60% NaH (600 mg, 15.0 mmol) in DMF (10 mL) at
0°C was added 4-(3,4-dimethylphenoxy)thiophenol (3.45 g, 15.0 mmol). To this solution of sodium
thiolate was then added a solution of iodide 2 in DMF (10 mL). The reaction, which became thick, was
stirred for 0.5 h at 0°C and then warmed to rt for 4 h. Water (100 mL) was then added and the mixture was

extracted with EA (3X). The combined extracts were washed with brine and dried over MgSO4.
Concentration gave a viscous oil which was purified by chromatography on silica gel eluting with
EA/hexane (15/85) to afford the corresponding sulfide (6.45 g, 86%): HRMS calcd for C28H37NSO5
400.1946, found 400.1948. Anal calcd for C28H37NSO4.1.75H2O C, 63.31; H, 7.68; N, 2.64; S, 6.04.
Found C, 63.36; H, 7.49; N, 2.86; S, 5.59.
To a solution of this sulfide (6.45 g, 13.0 mmol) in CH2Cl2 (100 mL) at 0°C was added 3-chloroperbenzoic
acid (4.45 g, 26.0 mmol) and the reaction was stirred at 0°C for 3 h. The solution was then washed with
water (2X) and brine and dried over MgSO4. Concentration gave a residue (10.5 g) which was
chromatographed on silica gel eluting with EA/hexane (20/80) to afford the corresponding sulphone 3f (5.7
g, 98%) as a colorless solid. Anal calcd for C28H37NSO7.H2O C, 61.18; H, 7.15; N, 2.55; S, 5.83. Found C,
61.32; H, 7.11; N, 2.44; S, 5.16.
Through a solution of the sulphone 3f (5.7 g, 13.0 mmol) in EA (120 mL) at 0°C was bubbled HCl gas for
15 min. Concentration and trituration of the residue with ether afforded the hydrochloride salt of the
secondary amine 4f (5.4 g, 89%) as a colorless solid: HRMS calcd for C23H30NSO5 432.1845, found
432.1828.
To a solution of the HCl salt of amine 4f in DMF (70 mL) was added K2CO3 (3.17 g, 23.0 mmol) followed
by propargyl bromide (0.98 mL, 23.0 mmol). The reaction was stirred for 4 h at rt and then diluted with
water (75 mL) and extracted with EA (3X). The combined organic extracts were washed successively with
water and brine and dried over MgSO4. Concentration gave a residue (6.28 g) which was chromatographed
on silica gel eluting with 1:1 EA/hexane to afford the propargyl amine ethyl ester 5f (4.28 g, 82%): 1H
NMR (400 MHz, CDCl3) δ 7.79 (2H, d, J = 9 Hz), 7.15 (1H, d), 7.04 (2H, d, J = 9 Hz), 6.86 (1H, s), 6.80
(1H, m), 4.19 (2H, q, J = 7 Hz), 3.44 (2H, s), 3.32 (2H, br s), 2.74 (2H, m), 2.69 (2H, m), 2.38-2.30 (3H,
m), 2.31 (3H, s), 2.28 (3H, s), 1.86 (2H, m), 1.31 (3H, t, J = 7 Hz). HRMS calcd for C24H31NSO5
469.1923, found 469.1908. Anal calcd for C24H31NSO5.0.5EA (consistent with NMR) C, 65.47; H, 6.87;
N, 2.73; S, 6.24. Found C, 65.50; H, 7.02; N, 2.66; S, 6.15.
To a solution of the propargyl amine ethyl ester 5f (4.13 g, 8.79 mmol) in 1:1 EtOH/THF (100 mL) was
added a solution of NaOH (3.52 g, 87.9 mmol) in H2O (30 mL) and the reaction was heated to 65°C for 40
h. The reaction was then concentrated to dryness and water (50 mL) was added, which was then acidified
to pH 2 with 2N HCl. Concentration gave a residue which was triturated with ether, filtered and dried to
afford the carboxylic acid 6f (3.8 g, 100%) as a colorless solid. HRMS calcd for C24H27NSO5 441.1608,
found 441.1651.
To a suspension of carboxylic acid 6f (1.0 g, 2.26 mmol) in CH2Cl2 (15 mL) was added triethylamine (0.95
mL, 6.78 mmol) and 50% aqueous hydroxylamine (1.5 mL, 22.6 mmol) followed by PyBroP (1.16 g, 2.48
mmol). After 3 d the reaction was concentrated to afford a residue which was chromatographed on a
reverse phase column eluting with a gradient of MeCN/H2O (30/70 to neat MeCN) to afford the requisite
hydroxamic acid free base 7f (215 mg, 21%) as a solid: Anal calcd for C24H28N2SO5 C, 63.14; H, 6.18;
N, 6.14; S, 7.02. Found C, 62.78; H, 6.06; N, 6.17; S, 6.86. To a suspension of this free base hydroxamic
acid (205 mg, 0.449 mmol) in MeOH (4 mL) at 0°C was added a solution of HCl in MeOH [prepared by
adding acetyl chloride (35 uL, 0.49 mmol) to MeOH (1 mL)]. The solution was concentrated to afford a
solid which was triturated with ether and dried to afford the monohydrochloride salt of the hydroxamic acid
7f (191 mg, 86%) as a colorless solid: MS MH+ calcd for C24H28N2SO5 457, found 457. Anal calcd for
C24H28N2SO5.HCl.0.5H2O C, 57.42; H, 6.02; N, 5.58; Cl, 7.06. Found C, 57.36; H, 6.32; N, 5.68; Cl, 6.84.
N-hydroxy-2-[(4-phenoxyphenyl)sulfonyl]acetamide (13). To a solution of 3-bromopyruvic acid hydrate
(1.95 g, 11.7 mmol) cooled to 0°C in MeOH (50 mL) was added 4-phenoxybenzenethiol 10 (2.35 g,
11.7mmol). The solution was stirred for 15 minutes followed by concentration in vacuo. The residue was
partitioned between EA and H2O and the organic layer was dried over MgSO4. Concentration in vacuo
provided the crude sulfide 11 as a yellow solid that was used without any additional purification. To a
solution of this sulfide of (1.2 g) in methanol/H2O cooled to 0 °C was added Oxone (3.5 g, 5.72 mmol). The
solution was stirred for 1 h followed by removal of excess Oxone by filtration. The filtrate was

concentrated and the residue was dissolved into EA and washed with saturated NaHC03 and brine and dried
over MgSO4. After concentration in vacuo the resulting residue was dissolved into MeOH and thionyl
chloride (1.9 mL, 26 mmol) was added. Chromatography (on silica, EA/hexane) provided the
decarbonylated sulphone 12 as a solid (350 mg, 44%). MS(CI) MH+ calculated for C15H1405S 307, found
307. To a solution of the sulphone 12 (350 mg, 1.1 mmol) in MeOH (2 mL) and THF (2 mL) was added
50% aqueous hydroxylamine (1 mL). The solution was stirred overnight. Trituration with EA provided the
hydroxamic acid 13 as a white solid (270 mg, 77%). HPLC 65 purity: >97%. MS(CI) MH+ calculated for
C14H13NO5S: 308, found 308.
N-hydroxy-2-methyl-2-[(4-phenoxyphenyl)sulfonyl]propanamide (17). To a solution of 4(phenoxy)benzenethiol (3.8 g, 18.8 mmol) in MeOH (60 mL) cooled to 0°C was added t-butyl
bromoacetate (2.8 mL, 18.8 mmol) and triethylamine (2.6 mL, 19.0 mmol). The solution was stirred for 30
minutes and was then concentrated in vacuo. The residue was partitioned between EA and H2O and the
organic layer was washed with brine and dried over MgSO4. Concentration in vacuo provided the sulfide as
an oil. To a solution of the sulfide in CH2Cl2 (85 mL) was added m-chloroperbenzoic acid (13.8 g, 43.2
mmol) over 15 minutes. The solution was stirred at rt for 2 h. The reaction was quenched by the addition of
aqueous Na2S03. After 30 minutes the solution was filtered through Celite. The filtrate was washed with
25 percent aqueous ammonia, IN HCl, and brine and dried over MgSO4. Chromatography on silica gel
eluting with EA/hexane provided the sulphone 14 as a white solid (4.0 g, 68%).
To a solution of the sulphone 14 (3.2 g, 9.2 mmol) in THF (65 mL) cooled to 0°C was added sodium
hydride (730 mg of a 60 percent dispersion in mineral oil, 18.4 mmol). After 10 minutes, methyl iodide
(2.28 mL, 36.8 mmol) was added dropwise and the mixture was stirred for 18 h at rt. The reaction was
quenched with H2O and concentrated in vacuo. The aqueous residue was diluted with EA and the organic
phase was washed with H2O and dried over Na2S04. Concentration in vacuo provided the dimethyl
sulphone 15 as an off-white solid (3.2 g, 92%). HPLC purity: 95%.
To a solution of the dimethyl sulphone 15 (3.2 g, 8.5 mmol) in anisole (10 mL) was added trifluoroacetic
acid (30 mL) and the solution was stirred for 30 minutes. Concentration in vacuo followed by trituration
(ethyl ether) provided the carboxylic acid 16 as a white solid (750 mg, 28%). HPLC purity: 99%. MS(CI)
MH+ calculated for C16H1605S: 321, found 321.
To a solution of the acid 16 (723 mg, 2.26 mmol) in DMF (4.5 mL) was added HOBT (366 mg, 2.71
mmol) and EDC (476 mg, 2.49 mmol). After the solution was stirred for 1 hour at rt 50% aqueous
hydroxylamine (0.40 mL, 6.8 mmol) was added. After 15 minutes the solution was partitioned between EA
and H2O. The organic layer was washed with H2O and brine and dried over Na2S04. Reverse phase
chromatography (MeCN/H2O) provided the hydroxamic acid 17 as a white foam (434 mg, 57%). HPLC
purity: 99%. MS(CI) MH+ calculated for C16H17NO5S: 342, found 342.
α-THP PhOPhCl (21)
In dry equipment under nitrogen, sodium metal (8.97 g, 390 mmol) was added to MeOH (1 l) at 0°C. The
reaction was allowed to warm to rt over 45 minutes by which time the sodium had completely dissolved.
The solution was chilled to 0°C and p-fluorothiophenol (41.5 mL, 0.39 mmol) was added, followed by
methyl 2-chloroacetate (34.2 mL, 0.39 mol). The reaction was stirred at rt for 4 h, filtered, and
concentrated in vacuo to give the desired sulfide (75.8 g, 97%) as a clear colorless oil. To a solution of this
sulfide (75.8 g, 0.38 mol) in MeOH (1 L) was added water (100 mL) and Oxone (720 g, 1.17 mol). An
exotherm to 67 °C was noted. After 2 h, the reaction was filtered and the cake was rinsed with MeOH. The
filtrate was concentrated in vacuo. The residue was taken up in EA and washed with brine, dried over
MgS04, filtered, and concentrated to give the sulphone 18 as a crystalline solid (82.74 g, 94%).
To a solution of the sulphone 18 (28.5 g, 0.123 mol) in DMF (200 mL) was added K2CO3 (37.3 g, 0.27
mol), bis-(2-bromoethyl) ether (19.3 mL, 0.147 mol), DMAP (0.75 g, 6 mmol), and tetra-nbutylammonium bromide (1.98 g, 6 25 mmol). The reaction was stirred for 18 h at rt. The reaction was then
slowly poured into 1N HCl (300 mL) and the resultant solid filtered and the cake washed well with

hexanes. The solid was recrystallized from EA/hexane to give the pyran 19 as a beige solid (28.7 g, 77%).
MS MH+ calcd for C13H15O5SF 303, found 303.
To the pyran methyl ester 19 (8.0 g, 26.5 mmol) in THF (250 mL) was added a solution of potassium
trimethylsilanoate (10.2 g, 79.5 mmol) in dry THF (15 mL). After 1.5 h, water (100 mL) was added and the
solution concentrated in vacuo. The residue was taken up in water and washed with EA. The aqueous
solution was acidified with 6N HCl to pH 1 and the resulting slurry was extracted with EA. The combined
extracts were washed with water, dried over Na2S04 and concentrated in vacuo. The residue was triturated
with hot ether and the resulting solid filtered and dried to give the carboxylic acid (5.78 g, 76%) as a
crystalline solid. HRMS MH+ calcd for C12H1305SF: 287.04, found 287.04. To a solution of the
carboxylic acid (9.1 g, 31.6 mmol) in DMF (70 mL) was added HOBT (5.1 g, 37.9 mmol), NMM (10.4
mL, 94.8 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxyIamine (11.5 g, 98 mmol), and EDC (8.48 g, 44.2
mmol). After three h at rt the reaction was concentrated in vacuo. The residue was taken up in EA, washed
successively with water, 5% KHS04, saturated aqueous NaHC03, brine, dried over Na2S04. Concentration
gave a residue which was purified by chromatography on silica gel eluting with EA/hexane to prove the
THP-hydroxamate 20 (9.7 g, 80%) as a crystalline solid: HRMS MH+ calculated for C17H22N06SF:
388.12, found 388.12.
To a solution of the THP-hydroxamate p-fluorophenyl sulphone 20 (2.9 g, 7.5 mmol) in DMF (15 mL) was
added p-chlorophenol (1.93 g, 15 mmol) and cesium carbonate (7.3 g, 22.5 mmol). The reaction was heated
to 90°C for 1.5 h. Additional DMF (20 mL) was added, followed by additional cesium carbonate (2 g, 6.2
mmol). The resulting mixture was heated to 95°C for 3 h. The reaction was then diluted with H2O and
extracted with EA. The organic layer was washed with brine and dried over Na2SO4. Concentration gave a
residue which was purified by chromatography on silica gel eluting with EA/hexane to afford the pchlorophenoxyphenyl sulphone THP-protected hydroxamate (2.9 g,78%). To a solution of this THPprotected hydroxamate (2.9 g, 5.7 mmol) in dioxane (5 mL) was added 4N HCl in dioxane (5 mL, 20
mmol), followed by MeOH (7.5 mL). The resulting solution was stirred at rt for 1 hour. Concentration and
reverse-phase chromatography eluting with MeCN/H2O provided the p-chlorophenoxyphenyl sulphone
hydroxamic acid 21 (1.35 g, 58%) as a white solid: MS (FAB) MH+ for C18H18N06SCl 412, found 412.
Alpha-Sulfide PhOPh 22
To a solution of ethyl isonipecotate 1 (26.2 g, 102 mmol) in THF (470 mL) at -45°C was added 2M LDA
in THF (60 mL, 120 mmol) with stirring. The solution was warmed to 0°C over 2 h and then recooled to 40°C, whereupon a solution of 4-phenyloxythiophenol disulfide (25.5 g, 63.0 mmol) in THF (30 mL) was
added. The reaction was then stirred at 0°C for 1 h, then warmed to rt for 16 h. Water (600 mL) was
added and the mixture was extracted with EA (3 X 500 mL). The combined organic extracts were washed
with brine and dried over MgSO4. Concentration gave a dark yellow oil (53 g) which was purified by
chromatography on silica gel eluting with EA/hexane (10/90) to give the desired sulfide 22 (24.7 g, 86%):
MS calcd for [C25H31NSO5-C5H9O2(BOC)] 358, found 358. 1H NMR (400 MHz, CDCl3) δ 7.87 (4H, m),
7.16 (1H, t, J = 7 Hz), 7.03 (2H, m), 6.92 (2H, m), 4.14 (2H, q, J = 7 Hz), 3.79 (2H, m), 3.12 (2H, m), 2.09
(2H, m), 1.72 (2H, m), 1.46 (9H, s), 1.23 (3H, t, J = 7 Hz).
N-BOC α-sulphone PhOPh 23
To a solution of sulfide 22 (1.8 g, 3.95 mmol) in CH2Cl2 (75 mL) at 0°C was added 3-chloroperbenzoic
acid (1.7 g, 7.9 mmol). The reaction was stirred for 1 h at 0°C, then 0.5 h at rt. The reaction solution was
then washed with water and brine and dried over MgSO4. Concentration gave a residue which was purified
by chromatography on silica gel eluting with EA/hexane (20/80) to afford the sulphone 23 (1.68 g, 87%) as
a colorless solid: DSC 137.1-139.3°C; MS MH+ calcd for [C25H31NSO7-C5H9O2(BOC)] 390, found 390.
Anal calcd for C25H31NSO7 C, 61.33; H, 6.38; N, 2.79; S, 6.55. Found C, 61.39; H, 6.45; N, 2.77; S, 6.54.
1
H NMR (400 MHz, CDCl3) δ 7.71 (2H, d, J = 8 Hz), 7.43 (2H, m), 7.25 (1H, m), 7.12-7.02 (4H, m), 4.21
(2H, q, J = 7 Hz), 4.16 (2H, m), 2.63 (2H, m), 2.32 (2H, m), 2.03 (2H, m), 1.44 (9H, s), 1.26 (3H, t, J = 7
Hz).
NH.HCl ethyl ester α-sulphone PhOPh 24

Through a solution of N-BOC ethyl ester 23 (3.65 g, 7.00 mmol) in EA (100 mL) at 0°C was bubbled HCl
gas for 5 min. The solution was concentrated to give a residue which was triturated with ether to afford
amine hydrochloride salt 24 (3.1 g, 100%) as a colorless solid: HRMS calcd for C20H23NSO5 390.1375,
found 390.1357. 1H NMR (400 MHz, d6-DMSO) δ 7.77 (2H, d, J = 11 Hz), 7.51 (2H, m), 7.32 (1H, t, J = 6
Hz), 7.18 (4H, d, J = 11 Hz), 4.12 (2H, q, J = 7 Hz), 3.41 (2H, br d, J = 14 Hz), 2.72 (2H, t, J = 11 Hz), 2.36
(2H, d, J = 14 Hz), 2.22 (2H, td, J = 11, 3 Hz), 1.08 (3H, t, J = 7 Hz).
N-BOC α-sulphone PhOPh (27a). To a solution of ethyl ester sulphone 23 (800 mg, 1.63 mmol) in 1:1
EtOH/THF (17 mL) was added NaOH (654 mg, 16.3 mmol) in H2O (3 mL) and the solution was heated to
65°C for 16 h. Concentration gave a beige semi-solid. Water (25 mL) was added and the mixture was
acidified to pH = 4 with 2N HCl and extracted with EA (2X). The combined organic extracts were washed
with brine and dried over MgSO4. Concentration gave the corresponding carboxylic acid 26a (754 mg,
100%) as a white foam: Anal calcd for C23H27NSO7 C, 59.86; H, 5.90; N, 3.04; S, 6.95. Found C, 59.49;
H, 6.37; N, 2.81; S, 6.56. MS MH+ calcd for [C23H27NSO7–C5H9O2 (BOC)] 362, found 362. 1H NMR
(400 MHz, CDCl3) δ 7.74 (2H, d, J = 10 Hz), 7.42 (2H, t, J = 8 Hz), 7.25 (1H, m), 7.09 (2H, d, J = 8 Hz),
7.03 (2H, d, J = 9 Hz), 4.18 (2H, m), 2.73 (2H, m), 2.28 (2H, m), 2.05 (2H, m), 1.45 (9H, s).
To a solution of carboxylic acid 26a (730 mg, 1.58 mmol) in DMF (9 mL) was added sequentially HOBT
(256 mg, 1.90 mmol), EDC (424 mg, 2.21 mmol), NMM (479 mg, 4.70 mmol) and 50% aqueous
hydroxylamine (1.04 mL, 15.8 mmol). After stirring for 16 h at rt, the reaction was recharged with
equivalent additional quantities of HOBT, EDC, NMM and hydroxylamine. After an additional 20 h at rt,
water (50 mL) was added and the mixture was extracted with EA (2 X 120 mL), and the combined extracts
were washed with brine and dried over MgSO4. Concentration gave a residue (820 mg) which was purified
by reverse-phase chromatography eluting with a gradient of MeCN/H2O (30/70 to 80/20) to afford the
desired hydroxamate 27a (460 mg, 61%): MS MH+ calcd for [C23H28N2SO7-C4H9O2(BOC)] 377, found
377. Anal calcd for C23H28N2SO7 C, 57.97; H, 5.92; N, 5.88; S, 6.73. Found 57.95; H, 6.02; N, 5.81; S,
6.85. IR (MIR) 1637, 1658 cm-1. 1H NMR (400 MHz, d6-DMSO) δ 9.14 (1H, br s), 7.71 (2H, d, J = 8 Hz),
7.49 (2H, t, J = 8 Hz), 7.28 (1H, t, J = 6 Hz), 7.16 (2H, d, J = 6 Hz), 7.11 (2H, d, J = 10 Hz), 3.96 (2H, m),
2.58 (2H, m), 2.28 (2H, m), 1.69 (2H, m), 1.39 (9H, s).
Hydroxamate NH.HCl α-sulphone PhOPh (27b). Through a solution of N-BOC hydroxamate 27a in
EA (25 mL) at 0°C was bubbled HCl gas for 5 min. The solution was allowed to stand at 0°C for 0.5 h and
was then concentrated to give a residue which was triturated with ether to afford the hydroxamate
hydrochloride salt 27b (330 mg, 99%) as a light pink solid: HRMS calcd for C18H20N2SO5 377.1171,
found 377.1170. 1H NMR (400 MHz, d6-DMSO) δ 9.28 (1H, s), 8.98 (1H, br s), 8.65 (1H, br s), 7.72 (2H,
d, J = 10 Hz), 7.51 (2H, m), 7.31 (1H, t, J = 7 Hz), 7.20-7.11 (4H, m), 3.38 (2H, m), 2.63 (2H, m), 2.45
(2H, m), 2.10 (2H, m). Anal calcd for C18H20N2SO5:HCl C, 52.36; H, 5.13; N, 6.78; Cl, 8.59; S, 7.77. Found
C, 51.95; H, 5.25; N, 6.55; Cl, 8.37; S, 7.63.
N-Me α-sulphone PhOPh (27c). To a solution of N-BOC α-sulphone 23 (2.67 g, 5.5 mmol) in CH2Cl2 (5
mL) was added trifluoroacetic acid (5 mL), and the solution was stirred at rt for 2 h. The solution was
concentrated in vacuo and the residue was triturated with ethyl ether to provide the crude amine
trifluoroacetic acid salt. To a solution of the crude amine salt in MeOH (10 mL) was added formaldehyde
(37% aqueous solution, 2.0 mL, 27.5mmol) and borane pyridine (2.2 mL, 22 mmol), and the solution was
stirred at rt for 18 h. The solution was concentrated in vacuo. The residue was dissolved in EA, washed
with H2O and dried over MgSO4. Concentration in vacuo provided the N-methyl amine 25c as a yellow oil
(2.17 g, 98%).
To a solution of the N-methyl α-sulphone 25c (2.17 g, 5.4 mmol) in EtOH (10 mL) and THF (10 mL) was
added NaOH (2.0 g, 50 mmol), and the reaction mixture w as stirred at 65°C for 18 h. The solution was
concentrated in vacuo. The residue was dissolved in H2O and extracted with ether. The aqueous solution
was acidified to pH 2 and the resulting solid was collected by vacuum filtration to provide the acid 26c (1.8
g, 90%) as a white solid.

To a solution of the acid 26c (0.5 g, 1.3 mmol) in DMF(10 mL) was added EDC (1.06 g, 5.5 mmol)
followed by O-tetrahydro-2H-pyran-2-yl-hydroxylamine (490 mg, 4.2 mmol) and 4-methylmorpholine
(0.76 mL) and the solution was stirred at rt for 18 h. The sb1ution was concentrated in vacuo and the
residue was dissolved to EA, washed with H2O and dried over MgSO4. Concentration in vacuo provided
the crude protected hydroxamate. To a solution of the crude hydroxamate in MeOH (10 mL) was added
acetyl chloride (0.28mL, 3.9 mmol), and the solution was stirred for 3 h at rt. The solution was
concentrated in vacuo. Reverse phase chromatography eluting with MeCN/H2O (0.01% HCl) provided the
α-sulphone hydroxamic acid 27c as a white solid (261 mg, 46%). MS(CI) MH+ calculated for C19H22N05S:391, found 391.
α-sulphone N-methoxyethyl PhOPh [patent EXAMPLE 30] (27d). To a solution of the amine HCI salt
24 (2.5 g, 5.87 mmol) and K2CO3 (1.6 g, 11.57 mmol) in DMF(25 mL) was added 2-bromoethylmethyl
ether (0.66 mL, 7.0 mmol) and then stirred at rt for 18 h. The solvent was evaporated and the residue was
diluted with EA. The organic layer was washed with water and dried over MgSO4. Concentration in vacuo
provided the methoxy ethyl amine 25c as light yellow oil (2.63 g, 100%).
To a solution of the methoxy ethyl amine 25c (2.63 g, 5.87 mmol) in THF (18 mL) and ethanol (18 mL)
was added NaOH (2.1 g, 5.25 mmol) in water(6 mL). The solution was heated to reflux for 12 h. The
solution was concentrated in vacuo and diluted with water. The aqueous layer was extracted with ether (2
X 100 mL) and was acidified to pH=2. Vacuum filtration of the resulting precipitation provided the acid
26das a white solid (2.4 g, 100%).
To a solution of the acid of part B (2.0 g, 4.33 mmol), also containing NMM (1.8 mL, 16.4 mmol), and Otetrahydro-2H-pyran-yl-hydroxylamine (0.767 g, 6.44 mmol) in DMF (20 mL) was added EDC (3.1 g, 16.2
mmol), and the solution was stirred at rt for 20 h. The solution was concentrated under high vacuum and
the residue was dissolved in EA. The organic layer was washed with H2O and dried over MgS04.
Concentration in vacuo provided the THP-hydroxamic acid as off white foam (1.60 g, 71.1%). To a
solution of this protected hydroxamate (1.58 g, 3.05 mmol) in MeOH (20 mL) at 0°C was added acetyl
chloride (0.65 mL, 9.15 mmol) and the solution was stirred at 0°C for 3 h. Concentration gave a residue
which was purified on reverse-phase chromatography on C-18 eluting with MeCN/H2O (0.01% HCl) to
afford the hydroxamate HCl salt 27d (0.65 g, 45.5%) as a white solid: Anal calcd for
C21H26N2O6S:HCl:0.75H2O C, 52.06; H, 5.93; N, 5.78; S, 6.62. Found C, 51.94; H, 5.67; N, 5.91; S, 6.66.
HRMS calcd for C21H26N2O6S 435.1590, found 435.1571.
N-cyclopropyl α-sulphone hydroxamate PhOPh (27e). To a solution of amine hydrochloride 24 (2.13 g,
5.0 mmol) in MeOH (25 mL) was added 3A molecular sieves (2 g) followed sequentially by acetic acid
(2.86 mL, 50 mmol), [(1-ethoxycyclopropyl)oxy]-trimethylsilane (6.08 mL, 30 mmol), and sodium
cyanoborohydride (1.41 g, 22.0 mmol) and the reaction was heated under reflux for 16 h. The mixture was
cooled and filtered, and then concentrated to give a residue (2.08 g) which was purified by chromatography
on silica gel eluting with EA/hexane (20/80) to afford the N-cyclopropyl amine 25e (1.90 g, 86%) as a
white solid: DSC 131.4-133.5°C. HRMS calcd for C23H27NSO5 429.1653, found 429.1600.
To a solution of N-cyclopropyl ethyl ester 25e (1.9 g, 4.2 mmol) in 1:1 EtOH/THF (25 mL) was added a
solution of NaOH (1.71 g, 4.3 mmol) in H2O (10 mL) and the reaction was heated to 65°C for 16 h. The
organic solvents were removed in vacuo and the reaction was diluted with additional water (20 mL).
Concentration to pH 5 with 1N HCl gave a solid which was filtered and dried to give the carboxylic acid
26e (1.49 g, 82%) as a colorless solid: HRMS calcd for C21H23NSO5 402.1375, found 402.1350.
To a solution of N-cyclopropyl carboxylic acid 26e (1.49 g, 3.4 mmol) in CH2Cl2 (50 mL) was added Et3N
(1.42 mL, 10.2 mmol) followed by 50% aqueous hydroxylamine (2.25 mL, 34.0 mmol) and PyBroP (3.17
g, 6.8 mmol). The reaction was stirred for 3 d at rt. Water (70 mL) was added and the reaction was
extracted with CH2Cl2 (3X). The combined organic extracts were washed with brine and dried over
MgSO4 and concentrated to give an oil (4.0 g) which was chromatographed on reverse phase eluting with
MeCN/H2O (20/80 to neat MeCN) to afford the free base hydroxamic acid (830 mg, 58%) as a solid. To a

solution of this hydroxamic acid amine (830 mg, 2.0 mmol) in MeOH (20 mL) was added methanolic HCl
[prepared by the addition of acetyl chloride (170 uL, 2.0 mmol) to MeOH (2 mL)]. The resulting
precipitate was filtered and dried to give the desired N-cyclopropylamine hydroxamic acid hydrochloride
salt 27e (595 mg, 66%) as a white powder: HRMS calcd for C21H24N2SO5 416.1407, found 416.1398.
Anal calcd for C21H24N2SO5.HCl C, 55.68; H, 5.56; N, 6.18; Cl, 7.83; S, 7.08. Found C, 55.39; H, 5.72; N,
6.15; Cl, 8.17; S, 7.29.
N-cyclopropylmethyl hydroxamate PhOPh (27f). To a solution of amine hydrochloride 24 (2.13 g, 5.0
mmol) in DMF (10 mL) at rt was added K2CO3 (1.4 g, 10.0 mmol) followed by bromomethylcyclopropane
(675 mg, 5.0 mmol) and the reaction was stirred for 16 h. Water (40 mL) was added and the mixture was
extracted with EA (2X). The combined extracts were washed with water and brine and dried over MgSO4.
Concentration gave a residue (2.94 g) which was purified by chromatography on silica gel eluting with
EA/hexane (20/80) to afford the cyclopropylmethyl amine 25f (2.09 g, 91%) as an oil which solidified: MS
MH+ calcd for C24H29NSO5 444, found 444. Anal calcd for C24H29NSO5 C, 64.99; H, 6.59; N, 3.16; S,
7.23. Found C, 64.99; H, 6.92; N, 3.18; N, 3.11; S, 7.28.
To a solution of cyclopropyl amine ethyl ester 25f (2.0 g, 4.4 mmol) in EtOH/THF (25 mL) was added a
solution of NaOH (1.75 g, 4.4 mmol) in water (10 mL) and the reaction was heated for 16 h at 65°C. The
organic solvents were removed in vacuo and additional water (20 mL) was added. Acidification to pH 4
gave a precipitate which was filtered and dried to give the carboxylic acid 26f (1.58 g, 79%) as a colorless
solid: HRMS MH+ calcd for C22H25NSO5 414.1375, found 414.1334. Anal calcd for
C22H25NSO5:HCl:0.5H2O C, 57.32; H, 5.90; N, 3.04. Found C, 57.44; H, 5.63; N, 3.13.
To a solution of carboxylic acid 26f (1.58 g, 3.50 mmol) in CH2Cl2 (50 mL) was added Et3N (1.46 mL,
10.5 mmol) followed by 50% aqueous hydroxylamine (2.31 mL, 3.50 mmol) and PyBroP (3.26 g, 6.99
mmol). After 3 d at rt the reaction was still a suspension so DMF (20 mL) was added and the reaction was
charged again with equivalent quantities of Et3N, aqueous hydroxylamine and PyBroP. After 24 h at rt,
water was added and the mixture was extracted with CH2Cl2. The combined extracts were washed with
water and brine and dried over MgSO4. Concentration gave an oil (5.0 g) which was purified by reverse
phase chromatography eluting with MeCN/H2O to afford the free base of the hydroxamate (3.2 g; theo =
1.51 g) contaminated with phosphoramide. To a solution of this free base in MeOH (5 mL) was added a
methanolic solution of HCl [prepared by adding acetyl chloride (0.25 mL, 3.5 mmol) to MeOH (20 mL) at
0°C]. Concentration gave an oil which was dissolved in a minimum amount of MeOH (2.5 mL) and added
slowly to ether (300 mL) with rapid stirring. The resulting solid was filtered and dried to afford the
requisite hydroxamic acid 27f (677 mg, 42% from 17i???) as a colorless powder.
N-propargyl ethyl ester PhOPh (27g). To a solution of amine hydrochloride salt 24 (850 mg, 1.99 mmol)
in DMF (20 mL) was added K2CO3 (300 mg, 2.0 mmol) followed by 80% propargyl bromide in toluene
(300 uL, 238 mg, 2.00 mmol) and the reaction was stirred for 4 h at rt. The reaction was quenched with the
addition of water and extracted with EA (3X). The combined organic extracts were washed with water and
brine and dried over MgSO4. Concentration gave a residue which was purified by chromatography on
silica gel eluting with EA/hexane (20/80) to afford N-propargyl amine 25g (740 mg, 86.5%) as colorless
crystals: DSC 94.4-98.3°C. IR (MIR) 3278, 1729 cm-1. Anal calcd for C23H25NSO5 C, 64.62; H, 5.89; N,
3.28; S, 7.50. Found C, 64.41; H, 5.65; N, 3.11; S, 7.27. 1H NMR (400 MHz, CDCl3) δ 7.73 (2H, d, J = 10
Hz), 7.42 (2H, t, J = 9 Hz), 7.23 (1H, m), 7.11 (2H, d, J = 7 Hz), 7.06 (2H, d, J = 9 Hz), 4.24 (2H, m), 3.28
(2H, m), 3.13 (2H, m), 2.52 (2H, m), 2.39 (2H, m).
To a solution of N-propargylamine ethyl ester 25g (660 mg, 1.50 mmol) in 1:1 EtOH/THF (20 mL) was
added NaOH (600 mg, 15.0 mmol) in water (10 mL) and the reaction was heated to 65°C for 18 h. Water
(40 mL) was added and the aqueous layer was washed with EA. Acidification of the aqueous layer to pH 5
with 2N HCl gave a solid which was filtered and rinsed successively with water and ether to afford
carboxylic acid 26g (519 mg, 80%) as a colorless solid: DSC 197.6-203.3°C. HRMS calcd for
C21H22NSO5 400.1219, found 400.1210. 1H NMR (400 MHz, d6-DMSO) δ 7.75 (2H, d, J = 10 Hz), 7.49
(2H, d, J = 8Hz), 7.28 (1H, t, J = 6 Hz), 7.18 (2H, d, J = 9 Hz), 7.12 (2H, d, J = 9 Hz), 3.28 (2H, s), 3.11

(1H, s), 2.80 (2H, m), 2.18 (2H, m), 2.06 (2H, m), 1.90 (2H, m). Anal calcd for C21H21NSO5:H2O C, 60.42;
H, 5.55; N, 3.36; S, 7.68. Found C, 60.60; H, 4.91; N, 3.33; S, 7.34.
To a suspension of carboxylic acid 26g (485 mg, 1.10 mmol) in DMF (10 mL) was added sequentially
EDC (326 mg, 1.70 mmol), NMM (364 uL, 3.30 mmol), and 50% aqueous hydroxylamine (0.73 mL, 11.1
mmol) and the reaction was stirred for 16 h at rt. An additional quantity of EDC (326 mg, 1.70 mmol) and
aqueous hydroxylamine (0.73 mL, 11.1 mmol) was added and the reaction was stirred for another 24 h at rt.
Water was added and the mixture was extracted with CH2Cl2. The combined extracts were washed with
brine and dried over MgSO4 and concentrated to afford a residue (380 mg) which was purified by reversephase chromatography eluting with MeCN/aqueous HCl (30/70 to 80/20) to afford the requisite
N-propargyl amine hydroxamic acid hydrochloride salt 27g (275 mg, 57%) as a colorless solid: HRMS
calcd for C21H23N2SO5 415.1328, found 415.1331. Anal calcd for C21H22N2SO5:HCl:0.5H2O C, 54.84; H,
5.26; N, 6.09. Found C, 54.90; H, 5.37; N, 6.07.
N-Ac EXAMPLE N-Ac α-sulphone PhOPh (27h). To a solution of N-BOC α-sulphone 23 (2.75 g, 5.6
mmol) in THF(10 mL) and EtOH (10 mL) was added NaOH (2.25 g, 56 mmol), and the solution was
heated to 70°C for 18 h. The solution was concentrated in vacuo, the residue was dissolved into H2O and
extracted with ethyl ether. The aqueous solution was acidified to a pH value of 2 and extracted with EA.
The organic layer was dried over MgSO4. Concentration in vacuo provided the crude acid as a solid. A
solution of the acid in CH2Cl2 (6 mL) and trifluoroacetic acid (6 mL) was stirred for 1 hour at rt.
Concentration in vacuo provided the amine hydrochloride salt as a solid (2.3 g, 100%). To a solution of
this amine hydrochloride salt (2.3 g, <5.6 mmol) in acetone (10 mL) and H2O (10 mL) cooled to 0 °C was
added triethylamine (1.17 mL, 8.4 mmol) and acetyl chloride (0.60 mL, 8.4 mmol), and the solution was
stirred at rt for 18 h. The solution was concentrated in vacuo to remove the acetone and the aqueous
solution was extracted with ethyl ether. The aqueous layer was acidified to pH 2 and extracted with EA.
The organic layer was dried over MgSO4 and concentration in vacuo provided the N-acetyl carboxylic acid
26h as a white solid (1.5 g, 65.2%).
To a solution of the N-acetyl carboxylic acid 26h (0.6 g, 1.49 mmol) in DMF (10 mL) was added EDC
(401 mg, 2.1 mmol) followed by 50% aqueous hydroxylamine (0.9 mL) and 4-methylmorpholine (0.7 mL,
6.4 mmol), and the solution was stirred for 18 h at rt. The solution was concentrated in vacuo and the
residue was dissolved into EA. The organic layer was washed with H2O and dried over MgSO4. Reverse
phase chromatography eluting with MeCN/H2O provided the N-acetyl hydroxamic acid 27h (101 mg,
16%) as a white solid: MS MH+ calcd for C20H22N2O6S 419, found 419.
N-methanesulphonyl hydroxamate PhOPh (27i). To a solution of amine hydrochloride 24 (2.13 g, 7.5
mmol) in CH2Cl2 (35 mL) was added triethylamine (2.34 mL, 16.5 mmol) followed by methanesulphonyl
chloride (0.70 mL, 9.0 mmol). After 16 h at rt the solution was washed with water (2X) and dried over
MgSO4. Concentration gave a dark oil (3.6 g) which was chromatographed on silica gel eluting with
EA/hexane(20/80 to 50/50) to afford the N-methanesulphonamide 25i (58%): MS calcd for C21H25NS2O7
468, found 468. Anal calcd for C21H25NS2O7 C, 53.95; H, 5.39; N, 3.00. Found C, 53.97; N, 5.43; N,
3.09.
To a solution of N-mesyl ethyl ester 25i (2.0 g, 4.15 mmol) in 1:1 EtOH/THF (25 mL) was added a solution
of NaOH (1.66 g, 41.5 mmol) in water (10 mL) and the reaction was heated to 65°C for 16 h. The organic
solvents were removed in vacuo, then additional water (20 mL) was added. The aqueous solution was then
acidified to pH 4 and extracted with EA (3X). The combined extracts were washed with brine, dried over
MgSO4 and concentrated to give the desired carboxylic acid 26i (1.46 g, 80%) as a light yellow foam:
HRMS calcd for C19H21NS2O7 440.0838; found 440.0820. Anal calcd for C19H21NS2O7 C, 51.92; H, 4.82;
N, 3.19; S, 14.59. Found C, 52.62; H, 5.18; N, 3.02; S, 13.85.
To a solution of N-mesyl carboxylic acid 26i (1.46 g, 3.38 mmol) in CH2Cl2 (50 mL) was added
sequentially Et3N (1.41 mL, 10.1 mmol), 50% aqueous hydroxylamine (2.2 mL, 33.8 mmol) and PyBroP
(3.16 g, 6.76 mmol). The reaction was stirred at rt for 3 d. Water (70 mL) was added and the mixture was
extracted with CH2Cl2 (3X). The combined extracts were washed with brine and dried over MgSO4.
Concentration gave a residue (3.5 g) which was purified by reverse-phase chromatography to afford the

desired methanesulphonamide hydroxamic acid 27i (215 mg, 14%) as a colorless solid: Anal calcd for
C19H22N2S2O7.H2O C, 48.29; H, 5.12; N, 5.93; S, 13.57. Found C, 48.72; H, 5.36; N, 5.61; S, 12.81.
p-fluoro disulfide 28
A solution of 4-fluorothiophenol (50.29 g, 390 mmoL) in DMSO (500 mL) was heated to 65°C for 6 hours.
The reaction was quenched by pouring into ice and the resulting solid was collected by vacuum filtration to
provide the disulfide 28 as a white solid (34.4 g, 68.9%): 1H NMR (300 MHz, CDCl3) δ 7.44 (4H, m), 7.01
(4H, m).
1-tert-butyl 4-ethyl 4-[(4-fluorophenyl)thio]piperidine-1,4-dicarboxylate (29). To a solution of ethyl
N-BOC-isonipecotate 1 (16.0 g, 62 mmoL) in THF (300 mL) at -50°C was added LDA (41.3 mL, 74
mmol) and the solution was stirred for 1.5 h at 0°C. To this solution was added p-fluorophenyl disulfide 28
(15.8 g, 62 mmoL), and the resulting solution was stirred at ambient temperature for 20 hours. The
reaction was quenched with the addition of H2O and the solution was concentrated in vacuo. The aqueous
residue was extracted with ethyl acetate and the organic layer was washed with 0.5N KOH, H2O, and brine.
Chromatography on silica eluting with hexane/ethyl acetate provided the sulfide 29 as an oil (18.0 g, 75%):
Anal calcd for C19H26NO4 C, 59.51; H, 6.83; N, 3.65; S, 8.36. Found C, 59.49; H, 7.03; N, 3.69; S, 8.28.
1-tert-butyl 4-ethyl 4-[(4-fluorophenyl)sulfonyl]piperidine-1,4-dicarboxylate (30). To a solution of the
sulfide 29 (16.5 g, 43 mmoL) in dichloromethane (500 mL) cooled to 0°C was added MCPBA (18.0 g, 86
mmoL) and the solution was stirred for 20 hours. The solution was diluted with H2O and extracted with
dichloromethane. The organic layer was washed with 10 percent Na2SO3, H2O, and saturated NaCl and
dried over magnesium sulfate. Chromatography on silica gel eluting with EA/hexane provided the
sulphone 30 as a solid (10.7 g, 60%). Anal calcd for C19H26O6NSF C, 54.93; H, 6.31; N, 3.37; S, 7.72.
Found 54.89; H, 6.43; N, 3.15; S, 7.57.
ethyl 4-[(4-fluorophenyl)sulfonyl]piperidine-4-carboxylate (31). Into a solution of the sulphone 30 (10
g, 24.0 mmol) in ethyl acetate (250 mL) was bubbled HCl gas for 10 minutes followed by stirring at
ambient temperature for 4 hours. Concentration in vacuo provided the amine hydrochloride salt 31 as a
white solid (7.27 g, 86%). Anal calcd for C14H18O4NSF.HCl C, 47.80; H, 5.44; N, 3.98; Cl, 10.08; S, 9.11.
Found C, 47.85; H, 5.65; N, 3.87; Cl, 10.35; S, 9.42.
N-hydroxy-1-methyl-4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxamide hydrochloride
(35a). To a solution of amine salt 37 (2.67 g, 5.14 mmol) and 37% aqueous formaldehyde (2.0 mL, 25.7
mmol) in MeOH (20 mL) was added borane pyridine complex (2.6 mL, 25.7 mmol). The solution was then
stirred at rt for 18 h. The solution was acidified and then concentrated to afford a residue that was
partitioned between aqueous NaHCO3 and EA. The aqueous layer was extracted with EA, and the
combined organic layers were washed with H2O and dried over MgSO4. Concentration gave the N-methyl
amine 33a as off-white foam (1.6 g, 76%).
To a solution of the methyl amine 33a (1.63 g, 3.88 mmol) in EtOH (20 mL) was added KOH (1.31 g, 23.2
mmol) in water (4 mL), and the resulting solution was heated to 50°C for 8 h, and then 70°C for 4 h. The
solution was acidified and concentrated providing the acid as white solid. To a solution of the crude acid in
DMF (50 mL) was added O-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.92 g, 7.76 mmol), NMM (1.05
mL, 7.76 mmol), and EDC (1.5 g, 7.76 mmol). The solution was stirred at rt for 72 h and then concentrated.
The residue was dissolved in EA and washed with aqueous NaHC03, H2O and dried over MgSO4.
Concentration in vacuo and chromatography on silica gel eluting with CH2Cl2/MeOH provided the THPhydroxamic acid 34a as white solid (0.46 g, 24.2%).
To a solution of the THP hydroxamic acid 34a (0.22 g, 0.45 mmol) in MeOH (5 mL) cooled to 0°C was
added acetyl chloride (0.096 mL, 13.5 mmol), and the resulting solution was stirred at rt for 3 h. The
solution was concentrated in vacuo and chromatographed on reverse phase eluting with MeCN/H2O (0.01%
HCl) to afford the hydroxamate N-methyl amine hydrochloride salt 35a (0.12 g, 60.6%) as a white solid:
HRMS calculated for C19H22N204S2 407.1099, found 407.1105.

1-ethyl-N-hydroxy-4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxamide hydrochloride (35b).
To a solution of amine hydrochloride 37 (6.2 g, 14 mmol) in DMF (20 mL) was added K2CO3 (3.87 g, 28
mmol) and iodoethane (2.4 g, 15.4 mmol) and the reaction was stirred at rt for 3 h. The mixture was then
diluted with EA (100 mL), washed with water and brine, and dried over MgSO4. Concentration gave the
N-ethyl amine 33b (6.1 g, 100%) as a solid: HRMS calcd for C22H27NS2O4 434.1460, found 434.1452.
To a solution of the N-ethylamine 33b (2.98 g, 6.9 mmol) in 1:1 EtOH/THF (40 mL) was added a solution
of NaOH (2.76 g, 69 mmol) in H2O (15 mL) and the reaction was heated to 65°C for 18 h. The reaction
was concentrated and resuspended in H2O (30 mL), acidified to pH 3. The resulting solid was filtered and
dried to afford the carboxylic acid (1.7 g, 61%) as a solid. HRMS calcd for C20H23NS2O4 406.1140,
found 406.1147. To a suspension of the carboxylic acid (5.3 g, 11.8 mmol) in DMF (45 mL) was added
sequentially HOBT (1.94 mg, 1.44 mmol), NMM (3.90 g, 35.4 mmol), O-tetrahydro-2H-pyran-2-ylhydroxylamine (2.07 g, 5.7 mmol) and EDC (3.17 g, 16.3 mmol). The reaction was stirred for 6 d and then
filtered to recover unreacted starting material. The filtrate was concentrated, then water was added and the
solution extracted with EA. The combined extracts were washed with brine and dried over MgSO4 and
concentrated to give a residue (970 mg) which was purified by chromatography on silica gel eluting with
MeOH/EA (3/97) to give the THP-hydroxamate 34b (2.33 g, 39%) as a white solid: HRMS calcd for
C25H32N2S2O5 505.1831, found 505.1831.
To a solution of THP-hydroxamate 34b (2.33 g, 4.6 mmol) in 1/3 MeOH/1,4-dioxane (20 mL) was added
4N HCl/1,4-dioxane (10 mL, 40 mmol). After stirring for 2 h at rt the reaction was concentrated to a semisolid which was purified by reverse-phase chromatography eluting with MeCN/H2O (HCl) (5/95 to 100%
MeCN) to afford the hydroxamic acid 235b (1.29 g, 55%) as a colorless foam: MS calcd for
C20H24N2S2O4 421, found 421. Anal calcd for C20H24N2S2O4:HCl:0.5H2O C, 51.55; H, 5.62; N, 6.01; S,
13.76; Cl, 7.61. Found C, 51.59; H, 5.73; N, 5.70; S, 13.71; Cl, 7.60.
N-hydroxy-1-(2-methoxyethyl)-4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxamide
hydrochloride (35c). To the solution of the amine hydrochloride salt37 (4.3 g, 9.43 mmol) and K2CO3
(2.62 g, 19.0mmol) in DMF(40 mL) was added 2-bromoethyl methyl ether (1.9 mL, 20.2 mmol). The
solution was stirred at rt for 48 h. Then DMF was evaporated and the residue was diluted with EA. The
organic layer was washed with water and dried over MgSO4. Concentration in vacuo provided the
methoxyethyl amine 33c (4.26 g, 95.3%) as white foam.
To a solution of the methoxyethyl amine 33c (4.26 g, 9.2 mmol) in 1:1 EtOH/THF (10 mL) was added
NaOH (3.7 g, 92.5 mmol) in water (9 mL). The solution resulting was heated to 60 °C for 12 h. The
solution was concentrated in vacuo, diluted with water, washed with ether, and acidified to pH 2. Filtration
of the resulting precipitate provided the corresponding carboxylic acid (3.5 g,87.5%) as a while solid. To a
solution of this carboxylic acid (3.4 g, 7.8 mmol) in DMF (20 mL) was added NMM (2.6 mL, 23.4 mmol),
HOBT (3.16 g, 23.4 mmol), and O-tetrahydro-2H-pyran-2-yl-hydroxylamine (1.85 g, 15.5 mmol) and EDC
(4.47 g, 23.4 mmol). The solution was stirred at rt for 36 h. The solution was concentrated and the residue
dissolved in EA. The organic layer was washed with saturated NaHC03, H2O, and dried over MgSO4.
Concentration provided the THP-protected hydroxamic acid 34c as off-white solid (2.98 g, 71.5%). To this
free base (2.98 g, 5.6 mmol) in MeOH (40 mL) at 0°C was added acetyl chloride (1.19 mL, 16.8 mmol),
and the resulting solution was stirred at the rt for 3 h. The solution was concentrated and purified on
reverse-phase chromatography eluting with MeCN/H2O (containing 0.01% HCl) provided the desired
hydroxamate N-methoxyethyl monohydrochloride salt 35c (2.29 g, 84.6%) as a white solid: Anal calcd for
C21H26N205S2 :HCl.O.9H2O C, 50.12; H, 5.77; N, 5.57; S, 12.74. Found: C, 50.41; H, 5.85; N, 5.73;
S,12.83.
1-cyclopropyl-N-hydroxy-4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxamide hydrochloride
(35d). To a solution of the amine TFA salt 37 (6 g, 11.9 mmol) was added acetic acid (6.8 mL, 119 mmol).
After 5 minutes stirring at rt, (l-ethoxylcyclopropyl)oxytriomethylsilane (14.3 mL, 71.4 mmol) was added
followed 5 minutes later by the addition of sodium cyanoborohydride (3.35 g, 53.6 mmol). Then the
solution was heated under reflux for 18 h. The solvent was evaporated and residue was dissolved in EA.
The organic layer was washed with IN NaOH, H2O and dried 40 over MgSO4. Concentration in vacuo gave
the N-cyclopropylamine 33d as an off-white powder (4.9 g, 92.6%).

To a solution of the cyclopropylamine 33d (4.88 g, 10.9 mmol) in THF (12 mL) and EtOH (12 mL) was
added NaOH (4.3 g, 100 mmol) in 45 water (25 mL). The solution was then heated to 55°C for 12 h and
was stirred at rt for 18 h. The solution was acidified to pH 2 and concentrated in vacuo to provide the acid
as white solid. To a solution of this crude acid in MeCN (50 mL) was added O-tetrahydro-2H-pyran-2-ylhydroxylamine (1.95 g, 16.3 mmol), NMM (2.4 mL, 21.9 mmol), and EDC (3.14 g, 16.3 mmol) in
sequence. The solution was then stirred at rt for 18 h. The solution was concentrated in vacuo and the
residue was dissolved in EA. The organic layer was washed with H2O and dried over MgSO4.
Concentration in vacuo provided the THP-protected hydroxamate 34d as a white solid (3.0 g, 60 53.1%).
To a solution of the THP-protected hydroxamate 34d (3 g, 5.8 mmol) in MeOH (45 mL) at 0°C was added
acetyl chloride (1.5 mL, 21.1 mmol), and the solution was stirred at rt for 2.5 h. Vacuum filtration of the
resulting precipitate provided the hydroxamic acid N-cyclopropylamine monohydrochloride salt 35d as a
white solid (1.84 g, 68.3%).
N-hydroxy-4-{[4-(phenylthio)phenyl]sulfonyl}-1-(vinylmethyl)piperidine-4-carboxamide
hydrochloride (35e). To a solution of amine hydrochloride 37 (4.78 g, 10.8 mmol) in DMF (25 mL) was
added K2CO3 (2.98 g, 21.6 mmol) followed by allyl bromide (0.935 mL, 10.8 mmol). The reaction was
stirred at rt for 5 h, then diluted with EA an washed successively with water and brine and dried over
MgSO4. Concentration gave an oil which was purified by chromatography on silica gel eluting with
EA/hexane (40/60) to give the desired N-allyl amine 33e (4.80 g, 99%) as an oil. MS MH+ calcd for
C23H22NS2O4 446, found 446. Anal calcd for C23H22NS2O4 C, 62.00; H, 6.11; N, 3.14; S, 14.39. Found C,
62.22; H, 6.28; N, 3.04; S, 4.09. 1H NMR (400 MHz, d6-DMSO) δ 7.64 (2H, d, J = 8 Hz), 7.58 (2H, m),
7.53 (3H, m), 7.31 (2H, d, J = 8 Hz), 5.74 (1H, m), 5.13 (1H, d, J = 15 Hz), 5.10 (1H, d, J = 11 Hz), 4.07
(2H, q, J = 7 Hz), 2.92-2.85 (4H, m), 2.17 (2H, m), 1.94 (2H, m), 1.72 (2H, m), 1.08 (3H, t, J = 7 Hz).
To a solution of N-allyl amine ethyl ester 33e (4.8 g, 10.8 mmol) in 1:1 EtOH/THF (50 mL) was added a
solution of NaOH (4.3 g, 10.8 mmol) in water (20 mL) and the reaction was heated at 65°C for 16 h. The
reaction was then concentrated to dryness and resuspended in water (100 mL) Acidification with 2N HCl
to pH 3 gave a precipitate which was filtered and dried to afford carboxylic acid (4.1 g, 84%) as a beige
solid: MS MH+ calcd for C21H23NS2O4 418, found 418. Anal calcd for C21H23NS2O4.HCl:H2O C, 53.44;
H, 5.55; N, 2.97; Cl, 7.51; S, 13.59. Found C, 53.36; H, 4.71; N, 2.90; Cl, 7.64; S, 14.13. To a suspension
of this carboxylic acid (4.1 g, 9.0 mmol) in DMF (90 mL) was added sequentially HOBT (1.46 g, 11
mmol), EDC (2.42 g, 13 mmol), NMM (2.97 mL, 27 mmol) and O-tetrahydro-2H-pyran-2-ylhydroxylamine (1.58 g, 13.5 mmol). The reaction was stirred for 3 d at rt and then concentrated to dryness.
The residue was redissolved in CH2Cl2 and washed with water and brine and dried over MgSO4.
Concentration gave a residue (5.97 g) which was purified by chromatography on silica gel eluting with
MeOH/EA (2/98 to 5/95) to afford the THP-hydroxamate 34e (4.11 g, 88%) as a colorless foam: HRMS
MH+ calcd for C26H32N2S2O5 517.1831, found 517.1830. Anal calcd for C26H32N2S2O5:0.25H2O C, 59.92;
H, 6.29; N, 5.37; S, 12.31. Found C, 59.63; H, 6.25; N, 5.79; S, 11.51. 1H NMR (400 MHz, d6-DMSO) δ
7.64 (2H, d, J = 8 Hz), 7.58 (2H, 2H, m), 7.52 (3H, m), 7.28 (2H, d, J = 8 Hz), 5.75 (1H, m), 5.12 (1H, d,
J= 18 Hz), 5.19 (1H, d, J = 9 Hz), 4.89 (1H, s), 4.00 (1H, t, J = 6 Hz), 3.46 (1H, d, J = 12 Hz), 3.83 (2H, d,
J = 7 Hz), 3.80 (1H, d, J = 12 Hz), 2.25 (2H, d, J = 10 Hz), 1.92-1.74 (4H, m), 1.77 (4H, m), 1.52 (4H, m).
To a solution of THP-hydroxamate 34e (4.11 g, 8.0 mmol) in EA (100 mL) at 0°C was added a methanolic
solution of HCl [generated by the addition of acetyl chloride (1.71 mL, 24.0 mmol) to methanol (20 mL)].
The solution was concentrated to give a gum which was triturated with ether to afford hydroxamate N-allyl
amine hydrochloride 35e (3.53 g, 95%) as a colorless powder: MS MH+ calcd for C21H24N2S2O4 433,
found 433. Anal calcd for C21H24N2S2O4:HCl:0.5H2O C, 52.76; H, 5.48; N, 5.86; S, 13.42; Cl, 7.42.
Found C, 52.57; H, 5.69; N, 6.29; S, 12.59; Cl, 7.80.
N-hydroxy-4-{[4-(phenylthio)phenyl]sulfonyl}-1- (2-propynyl)-4-piperidinecarboxamide,
monohydrochloride (SC-276, hydrochloride salt). To a solution of the amine hydrochloride salt 31 (5.98
g, 17.0 mmol) in DMF (120 mL) was added potassium carbonate (4.7 g, 34.0 mmol) followed by propargyl
bromide (2.02 g, 17.0 mmol) and the solution was stirred for 4 hours at ambient temperature. The solution

was partitioned between EA and H2O, and the organic layer was washed with H2O and brine and dried over
magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the propargyl amine 32f as
a yellow oil (5.2 g, 86%).
To a solution of the propargyl amine 32f (2.75 g, 7.78 mmol) in DMF (15 mL) was added thiophenol (0.80
mL, 7.78 mmol) and CsCO3 (2.79 g, 8.56 mmol) and the solution was heated to 70°C for 6 hours. The
solution was partitioned between ethyl ether and H2O. The organic layer was washed with H2O and
saturated NaCl, and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane)
provided the thioether 33f as an oil (1.95 g, 56%). MS MH+ calcd for C23H25NO4S2 444, found 444. Anal
calcd for C23H25NO4S2 C, 62.28; H, 5.68; N, 3.16; S, 14.46. Found C, 62.27; H, 5.81; N, 3.09; S, 14.32.
1
H NMR (300 MHz, CDCl3) δ 7.61 (2H, d, m), 7.54 (2H, m), 7.46 (3H, m), 7.20 (2H, m), 4.21 (2H, q, J = 7
Hz), 3.26 (2H, d, J = 2 Hz), 2.89 (2H, m), 2.34 (2H, m), 2.21 (1H, t, J = 2 Hz), 2.17-2.11 (4H, m), 1.23 (3H,
t, J = 7 Hz).
To a solution of the ethyl ester 33f (1.81 g, 4.06 mmol) in ethanol (21 mL) and H2O (3.5 mL) was added
KOH (1.37 g, 24.5 mmol) and the solution was heated to 105 degrees Celsius for 4.5 hours. The solution
was acidified to a pH value of 1 with concentrated HCl solution and then concentrated to provide the acid
as a yellow residue that was used without additional purification (1.82 g). To a solution of the carboxylic
acid (1.82 g, 4.06 mmol) in acetonitrile (20 mL) was added O-tetrahydro-2H-pyran-2-yl-hydroxylamine
(723 mg, 6.17 mmol) and triethylamine (0.67 mL, 4.86 mmol). To this solution was added EDC (1.18 g,
6.17 mmol) and the solution was stirred for 18 hours. The solution was partitioned between H2O and ethyl
acetate. The organic layer was washed with H2O, saturated NaHCO3 and brine and dried over magnesium
sulfate. Chromatography on silica eluting with ethyl acetate/hexane provided the THP-hydroxamate 34f
(1.32 g, 63%) as a white solid: MS MH+ calcd for C26H31N2O5S2 515, found 515. 1H NMR (300 MHz,
CDCl3) 7.65 (2H, d, J = 8 Hz), 7.55 (2H, m), 7.50-7.43 (3H, m), 7.18 (2H, d, J = 8 Hz), 4.98 (1H, br s),
3.99 (1H, t, J = 11 Hz), 3.68 (1H, d, J = 11 Hz), 3.22 (2H, d, J = 2 Hz), 2.91 (2H, dd, J = 10, 2 Hz), 2.32
(2H, td, J = 11, 2 Hz), 2.27-2.16 (4H, m), 1.92-1.73 (3H, m), 1.68-1.55 (3H, m).
To a solution of the THP-hydroxamate 34f (9.65 g, 18.7 mmol) in methanol (148 mL) cooled to 0°C was
added acetyl chloride (4.0 mL, 56.2 mmol), and the solution was stirred for 45 minutes at rt. Concentration
followed by trituration with ethyl ether provided 35f (SC-276) as a white solid (8.10 g, 94%). MS(CI) MH+
calculated for C21H22N2O4S2: 431, found 431. Anal calcd for C21H22N2O4S2.HCl C, 52.99; H, 5.08; N,
5.88; S, 13.47. Found C, 53.02; H, 5.21; N, 5.82; S, 13.08. 1H NMR (300 MHz, MeOD) δ 7.67 (2H, d, J =
8 Hz), 7.57 (2H, m), 7.53-7.47 (3H, m), 7.26 (2H, d, J = 7 Hz), 4.08 (2H, d, J = 2 Hz), 3.74 (2H, br d, J = 3
Hz), 3.39 (1H, t, J = 2 Hz), 3.02 (2H, br t, J = 13 Hz), 2.61 (2H, br d, J = 14 Hz), 2.39 (2H, br t, J = 13 Hz).
N-hydroxy-4-{[4-(phenylthio)phenyl]sulfonyl}-1- (2-propynyl)-4-piperidinecarboxamide,
methanesulphonate (SC-276, mesylate salt). To a solution of the free base of SC-276 (1.61 g, 3.7 mmol)
in MeOH (10 mL) was added methane sulphonic acid (395 mg, 4.1 mmol). After 3 h at rt the precipitate
was isolated by filtration to afford the mesylate salt of SC-276 (1.60 g, 81%) as a colorless crystalline
solid: Crystalline by powder X-ray diffraction. DSC 219.7°C. Anal calcd for C21H22N2O4S2.CH3SO3H C,
48.51; H, 5.18; N, 5.14; S, 17.66. Found C, 48.88; H, 5.15; N, 5.23; S, 17.81.
1-acetyl-N-hydroxy-4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxamide (35f). To a solution
of N-BOC ethyl ester 30 ((40 g, 96 mmol) and K2CO3 (26 g, 188 mmol) in DMF (200 mL) at 0°C was
added thiophenol (19.8 mL, 192 mmol) and the reaction was stirred at rt for 36 h. Concentration gave a
residue which was dissolved in EA and washed with water and brine and dried over MgSO4.
Chromatography on silica gel eluting with EA/hexane gave the diaryl sulfide (44.3 g, 91%) as a white
solid. To a solution of the diaryl sulfide ethyl ester (7 g, 1.29 mmol) in 1:1 EtOH/THF (50 mL) was added
NaOH (5.1 g, 12.9 mmol) in H2O (50 mL). The solution was heated to reflux for 20 h. The solution was
then concentrated in vacuo and the residue was dissolved in H2O. The aqueous layer was extracted with
ether, and then acidified to pH 2 and extracted with EA. The combined organic extracts were washed with
water and brine and dried over MgSO4. Concentration provided the carboxylic acid (3.9 g, 60%) as white
foam. To a solution of this N-BOC carboxylic acid (2.3 g, 4.98 mmol) in CH2Cl2 (6 mL) was 5 added TFA
(6 mL, 77.8 mmol), and the solution was stirred at rt for 1 h. Concentration in vacuo provided the amine

trifluoroacetate salt (2.44 g, 100%) as white foam. To a solution of this trifluoroacetate salt (5.0 g, 12.1
mmol) and triethylamine (8.7 mL, 60.4 mmol) in 1:1 acetone/water (20 mL) at 0°C was added acetyl
chloride (4.6 mL, 36 mmol), and the solution was stirred at rt for 40 h. The mixture was concentrated and
the aqueous layer acidified to pH 2. This aqueous layer was extracted with EA and the combined organic
extracts were washed with water and dried over MgS04. Concentration in vacuo provided the N-acetamide
carboxylic acid (5.0 g, 100%) as light yellow foam. To a solution of the acetamide (5 g, 11.9 mmol) in
DMF (50 mL) was added NMM (5.3 mL, 47.6 mmol), HOBT (4.8 g, 35.7 mmol), O-tetrahydro-2H-pyranyl-hydroxylamine (2.8 g, 23.5 mmol) and EDC (6.8 g, 35.7 mmol), and the solution was stirred at rt for 20
h. The reaction was concentrated under vacuum and the residue was dissolved in EA. The organic layer
was washed with saturated NaHC03, KHS04, H2O and dried over MgSO4. Concentration in vacuo provided
the THP-protected hydroxamic acid 34g (6.07 g, 98.2%) as a colorless foam.
To a solution of the THP-hydroxamate 34g (6.07 g,11.7 mmol) in MeOH (100 mL) at 0°C was added
acetyl chloride (2.5 mL, 35.1 mmol), and the solution was stirred at rt for 3 h. Concentration gave a residue
which was purified by chromatography on silica gel eluting with methanol/ CH2Cl2 to provide the N-acetyl
hydroxamic acid (3.3 g, 65%) as a white solid.
N-hydroxy-1-(methylsulfonyl)-4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxamide (35g). To
a solution of amine hydrochloride 37 (2.0 g, 4.7 mmol) in CH2Cl2 (35 mL) was added NMM (1.29 mL,
11.7 mmol) followed by methanesulphonyl chloride (0.55 mL, 7.05 mmol). The reaction was stirred for 2
d at rt and then concentrated. Water was added and the mixture was extracted with EA (3X). The
combined extracts were washed with water and brine and dried over MgSO4. Concentration gave the
methanesulphonamide 33h (2.17 g, 95%) as colorless crystals: 1H NMR (400 MHz, CDCl3) δ 7.62-7.52
(4H, m), 7.47 (3H, m), 7.21 (2H, d, J = 9 Hz), 4.23 (2H, q, J = 7 Hz), 3.85 (2H, m), 2.77 (3H, s), 2.63 (2H,
t, J = 11 Hz), 2.46 (2H, d, J = 13 Hz), 2.17 (2H, m), 1.26 (3H, t, J = 7 Hz).
To a solution of mesyl ethyl ester 33h (2.1 g, 4.3 mmol) in 1:1 EtOH/THF (50 mL) was added a solution of
NaOH (1.72 g, 43 mmol) in H2O (10 mL) and the reaction was heated on at 60°C. Concentration gave a
residue which was acidified to pH 2 with 2N HCl and extracted with EA. The combined extracts were
washed with brine and dried over MgSO4 and concentrated to give the desired carboxylic acid (2.1 g,
100%) as a solid: 1H NMR (400 MHz, CDCl3) δ 7.67 (2H, d, J = 8 Hz, 7.56 (2H, m), 7.57 (3H, m), 7.24
(2H, d, J = 11 Hz), 3.89 (2H, dt, J = 14, 3 Hz), 2.97 (1H, t, J = 12 Hz), 2.69 (2H, t, J = 11 Hz), 2.14 (2H, br
d, J = 13 Hz), 1.75 (2H, qd, J = 11, 3 Hz). To a solution of this carboxylic acid (1.98 g, 4.3 mmol) in DMF
(30 mL) was added HOBT (705 mg, 5.2 mmol), NMM (1.42 g, 12.9 mmol), O-tetrahydro-2H-pyran-2-ylhydroxylamine (755 mg, 6.5 mmol) and EDC (1.17 g, 6.1 mmol). The reaction was stirred 4d at rt, then
diluted with water and extracted with EA. The combined organic extracts were washed with water and
brine and dried over MgSO4. Concentration gave a yellow oil (3.86 g) which was purified by
chromatography on silica gel eluting with EA/hexane (30/70) to afford the THP-hydroxamate 34h (1.99g,
MS MH+ calcd for C24H30N2S3O7 555, found 555. 1H NMR (400 MHz, CDCl3) δ 9.49 (1H, s), 7.65 (2H, d,
J = 6 Hz), 7.57 (2H, m), 7.57 (3H, m), 7.19 (2H, d, J = 7 Hz), 4.98 (1H, s), 3.98 (1H, t, J = 10 Hz), 3.82
(2H, m), 3.69 (1H, m), 3.86 (2H, qd, J = 10, 3Hz), 2.73 (3H, s), 2.28 (2H, m), 2.19 (2H, m), 1.90-1.76 (3H,
m), 1.72-1.58 (3H, m).
To a solution of the THP-hydroxamate 34h (1.86 g, 3.5 mmol) in MeOH/1,4-dioxane (40 mL) was added
4N HCl in 1,4-dioxane (20 mL, 80 mmol). The reaction was stirred for 2.5 h at rt and then concentrated to
dryness. Trituration with ether gave the desired N-mesyl hydroxamic acid 35h (1.48 g, 91%) as a light
pink solid: HRMS calcd for C19H22N2S3O6 471.0718, found 471.0728. Anal calcd for C19H22N2S3O6:Et2O
C, 50.72; H, 5.92; N, 5.14; S, 17.66. Found C, 50.25; H, 5.59; N, 5.12; S, 17.83.
1-tert-butyl 4-ethyl 4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-1,4-dicarboxylate (36). To a solution
of sulphone 30 (40 g, 96 mmol) and powdered K2CO3 (26 g, 188 mmol) in DMF (200 mL) cooled to 0°C
was added thiophenol (19.8 mL, 192 mmol), and the resulting composition was then stirred at rt for 36 h.
That solution was concentrated under high vacuum and the residue was dissolved in EA. The organic layer
was washed with H2O and dried over MgSO4. Chromatography on silica gel eluting with EA/ hexane
provided the phenylthiophenyl BOC-sulphone 36 as a white solid (44.3 g, 91%).

ethyl 4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxylate hydrochloride (37, hydrochloride
salt). Through a solution of N-BOC ethyl ester 36 (31.2 g, 66 mmol) in EA (500 mL) at 0°C was bubbled
HCl gas for 0.5 h. The solution was allowed to stand for an additional 1.5 h and was then concentrated to
afford a residue which was triturated with ether to afford amine hydrochloride 37 (26.9 g, 96%) as a white
foam.
ethyl 4-{[4-(phenylthio)phenyl]sulfonyl}piperidine-4-carboxylate trifluoroacetate (37, trifluoroacetate
salt). To a solution of the phenylthiophenyl BOC-sulphone (8.6 g, 17 mmol) in CH2Cl2 (30 mL) cooled to
0°C was added TFA (30 mL), and the resulting solution was stirred at rt for 2 h. Concentration in vacuo
provided the amine TFA salt as a light yellow gel (8.7 g, 100%).
Enzyme Assays. Inhibitors were assayed against purified hMMP-1 hMMP-2, hMMP-8, hMMP-9, and
hMMP-13 using an enzyme assay based on cleavage of the fluorogenic peptide MCA-Pro-Leu-Gly-LeuDpa-Ala-Arg-NH2. Human MMP-3 activity was measured using a fluorogenic substrate containing
glutamic acid and (S)-2-aminopentanoic acid [Nagase, H., Fields, C.G., and Fields, G.B. Design and
characterization of a fluorogenic substrate selectively hydrolysed by stromelysin 1 (matrix
metalloproteinase-3). J. Biol. Chem. 1994, 269, 20952-20957.] Assay conditions were similar to those
described in G. Knight et al. in FEBS Lett. 1992, 296, 263. All basic compounds were tested as their
hydrochloride salts unless otherwise indicated.
Mouse Corneal Neovascularization Model. Animal work was carried out in accordance with institutional
guidelines. All animal procedures were approved the Institutional Animal Care and Use Committee and
conform to the HIH Guidelines for the Ethical Care and Treatment of Animals. A Hydron
[poly(hydroxyethyl)methacrylate: IFN Sciences, New Brunswick, NJ] implant containing 60 ng of human
recombinant bFGF (Life Technologies, Gaithersburg MD) and 200 µg of sucralfate (Carafate: Marion
Merrel Dow, Cincinnati, OH) were prepared and stored at -90ºC. C57BL/6 male mice (Charles River
Laboratories, Raleigh, NC) weighing 200-250 g were anesthetized , and a 2-mm keratotomy was made 1
mm from the center of the globe with #15 surgical blade. An intrastromal pocket was tunneled toward the
lateral canthus using a modified corneal knife (1 X 15), and a single Hydron pellet was inserted ~2mm
from the conral-scleral junction. In some cases, mice were implanted with Hydron pellets prepared without
bFGF. Treatment of mice with SC-276 or vehicle was initiated the evening of the same day. SC-276 was
prepared in vehicle (0.5% methylcellulose, 0.1% polysorbate 80 in water; sterile filtered). Seven days later,
the mice were injected in the ipsilateral carotid artery with 50% India ink to stain the blood vessels. The
rats were sacrificed; the corneas were removed and mounted on microscope slides; and the area of corneal
vascularization was measured using computer-assisted image analysis.

MX-1 human breast carcinoma model

Female NCr-nude mice were implanted subcutaneously with 1 mm3 MX-1 human breast carcinoma
fragments in the flank. Tumors were monitored initially twice weekly, and then daily as the neoplasms
approached the desired size. When the majority of the carcinomas reached a mass of 32-126 mg in
calculated tumor weight, the animals were pair-matched into treatment groups. Estimated tumor weight
was calculated using the formula: tumor weight (mg) = [w2 X L]/2, where w= tumor width and L = tumor
length, measured in mm.

SC-276 was prepared in vehicle (0.5% methylcellulose, 0.1% polysorbate 80 in water; sterile filtered).
Taxol (Taxol®; Bristol Myers Squibb) was obtained as the marketed pharmaceutical drug. Taxol was
given ip on a daily X 5 schedule at a dose of 9 mg/kg. SC-276 was given b.i.d. orally at 100 mg/kg until the
study end-point was reached. All drugs were administered starting the day of pair match (Day 1). In the
combination group, the oral dose of SC-276 immediately followed the Taxol injection. The vehicletreated mice served as controls and were dosed orally b.i.d. with vehicle until the study end point was
reached.

The median survivals of various groups were compared to each other and to the median survival time of
MX-1 growth control mice. Mice were euthanized when MX-1 tumors reached a calculated size of 1.5 g
and is considered a cancer death. The median survival (MDS) is the day at which half the mice in a group
have died. Survival curves were compared using Graphpad Prism.
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Table 1. In Vitro MMP Inhibitory Data [IC50 Values (nM)] and Oral Rat PK Data [Cmax and C6h (µg/mL)] of β-sulphones 7
O

O
HO
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N
H
X

Cmpd
RS-130830
7a
7b
7c
7d
7e
7f

X
O
NBOC
NH
N-3-MeOBn
NCH2CH2Ph
N-propargyl
N-propargyl

Ar
p-ClPh
Ph
Ph
Ph
Ph
Ph
3,4-diMePh

MMP-1
800
475
2400
330
700
485
7700

MMP-2
0.4
0.2
2.8
0.2
0.3
0.3
0.9

Ar

MMP-3
17.5
158
18.1
42.5
35.0
18.1

7a-f

MMP-8
1.8
2.4
0.40
3.0
0.60
0.70

MMP-9
1.0
30.0
1.1
9.0
4.5
7.0

MMP-13
0.6
0.2
8.0
0.4
1.1
0.6
0.8

Cmax
1372
1095
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8038
1455

C6h
537
12
5
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Table 2. In Vitro MMP Inhibitory Data (IC50 Values, nM) and Oral Rat PK of RS 130,830 and the corresponding α-sulphone 21
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Table 3. In Vitro MMP Inhibitory Data [IC50 Values (nM)] and Oral Rat PK Data [Cmax and C6h (µg/mL)] of Phenyloxyphenyl α-sulphones 27a-i
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0.2
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0.2

59
0.3
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0.29
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Table 4. In Vitro MMP Inhibitory Data (IC50 Values (nM) and Oral Rat PK Data (Cmax and C6h (µg/mL) of Phenylthiophenyl α-sulphones 35a-g
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35a
35b
35c
35d
35e
SC-276
35f
35g
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CH3
Et
Methoxyethyl
Cyclopropyl
Allyl
Propargyl
Acetyl
Mesyl

MMP-1
>10,000
>10,000
>10,000
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9000
7300
>10,000

MMP-2
0.5
0.8
0.3
0.1
0.15
0.2
0.4
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13.0
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12,589
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72
-

t1/2 (h)
1.91
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BA (%)
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28
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-

Figure 3: β-sulphone versus α-sulphones (MMP IC50 values, nM; rat PK 20 mpk suspension, µg/mL)
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SC-276 inhibits angiogenesis in the mouse cornea. Neovascularization was initiated in the
mouse cornea by implanting a Hydron pellet containing basic FGF pellet. SC-276, at doses of 150 mg/kg in 0.5% methylcellose/0.08% tween 80 was administered orally twice a day for 5 days.

Neovascularization in the control and treated groups was measured and the extent of
neovascularization in treatment groups was normalized to vehicle-treated control (set at 100%).
This is representative data from two independent experiments.

Figure 7
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SC-276 extends the survival of MX-1 breast-tumor bearing mice treated with Taxol. Mice were
implanted with MX-1tumor fragment and then pair-matched on Day 1 when the tumors reached approx
60mg. Groups were administered vehicle, SC-276, Taxol or the combination of Taxol and SC-276 from
Day 1 until the end point was reached.

Table 5

Summary of Treatment Response

Drug 1

Drug 2

MDS

P value

Vehicle

-

26.0

-

Taxol

-

31.0

*p=0.0001

-

SC-276

33.0

**p<0.0001

Taxol

SC-276

54.5

***p=0.0004

*p, Vehicle vs Taxol
**p, Vehicle vs SC-276
***p, Taxol vs combination Taxol/SC-276

